U.S. Physical Therapy, Inc(NYSE:USPH) 
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injurie...
Website: http://www.usph.com
Full Time Employees: 3,200
Sector: Healthcare
Industry: Medical Care Facilities
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2016-12-31 | 2015-09-30 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2013-03-13 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net patient revenue | 164,024,000 | 164,183,000 | 150,061,000 | 139,146,000 | 140,271,000 | 131,075,000 | 131,452,000 | 127,243,000 | 129,280,000 | 120,146,000 | 116,710,000 | 118,196,000 | 109,538,000 | 113,511,000 | 112,327,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
other revenue | 33,108,000 | 33,161,000 | 30,386,000 | 28,887,000 | 26,919,000 | 24,600,000 | 23,349,000 | 22,764,000 | 22,205,000 | 21,036,000 | 22,892,000 | 22,460,000 | 22,166,000 | 16,322,000 | 13,566,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net revenue | 197,132,000 | 197,344,000 | 180,447,000 | 168,033,000 | 167,190,000 | 155,675,000 | 154,801,000 | 150,007,000 | 151,485,000 | 141,182,000 | 139,602,000 | 140,656,000 | 131,704,000 | 129,833,000 | 125,893,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
yoy | 17.32% | 18.04% | 16.57% | 12.02% | 10.37% | 9.65% | 7.45% | 7.70% | 8.74% | 10.89% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
qoq | -0.11% | 7.39% | 0.50% | 7.40% | 0.56% | 3.20% | -0.98% | 1.13% | -0.75% | 6.80% | 1.44% | 3.13% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating cost: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
salaries and related costs | 116,619,000 | 113,788,000 | 109,494,000 | 99,835,000 | 96,334,000 | 93,731,000 | 90,633,000 | 89,846,000 | 86,871,000 | 82,317,000 | 81,786,000 | 79,939,000 | 75,149,000 | 75,296,000 | 70,492,000 | 68,866,000 | 63,815,000 | 65,677,000 | 57,519,000 | 43,429,000 | 69,004,000 | 70,549,000 | 66,748,000 | 70,669,000 | 64,451,000 | 46,594,000 | 41,802,000 | 40,109,000 | 37,942,000 | 36,522,000 | 35,733,000 | 35,813,000 | 34,415,000 | 34,415,000 | 33,978,000 | 33,376,000 | 32,671,000 | 32,799,000 | 23,297,250 | 32,430,000 | 31,120,000 | 29,639,000 | 28,466,000 | 27,991,000 | 27,644,000 | 26,771,000 | 27,081,000 | 26,823,000 | 26,430,000 | 25,403,000 | 25,686,000 | 25,661,000 | 24,821,000 | 24,101,000 | 23,624,000 | 19,579,000 | 18,072,000 | 17,916,000 | 18,467,000 | |||||||||||
rent, supplies, contract labor and other | 36,115,000 | 34,127,000 | 18,480,000 | 33,914,000 | 35,277,000 | 31,916,000 | 32,080,000 | 30,707,000 | 30,844,000 | 29,678,000 | 29,696,000 | 28,345,000 | 28,662,000 | 25,961,000 | 24,239,000 | 22,416,000 | 21,420,000 | 21,421,000 | 19,695,000 | 20,311,000 | 22,909,000 | 23,143,000 | 22,166,000 | 23,026,000 | ||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 5,495,000 | 5,741,000 | 1,090,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provision for credit losses | 2,073,000 | 1,995,000 | 1,847,000 | 1,721,000 | 1,717,000 | 1,572,000 | 1,525,000 | 1,563,000 | 1,356,000 | 1,336,000 | 1,551,000 | 1,305,000 | 1,383,000 | 1,358,000 | 1,364,000 | 1,200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on clinic closures - lease and other | -42,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total operating cost | 160,260,000 | 155,720,000 | 147,920,000 | 138,902,000 | 133,328,000 | 127,274,000 | 124,285,000 | 122,078,000 | 119,278,000 | 113,351,000 | 112,818,000 | 109,835,000 | 105,116,000 | 102,650,000 | 96,094,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gross profit | 36,872,000 | 41,624,000 | 32,527,000 | 29,131,000 | 33,862,000 | 28,401,000 | 30,516,000 | 27,929,000 | 32,207,000 | 27,831,000 | 26,784,000 | 30,821,000 | 26,588,000 | 27,183,000 | 29,799,000 | 34,304,000 | 25,896,000 | 29,118,000 | 30,357,000 | 19,284,000 | 15,691,000 | 26,959,000 | 27,372,000 | 31,425,000 | ||||||||||||||||||||||||||||||||||||||||||||||
yoy | 26.57% | 22.92% | 6.59% | 4.30% | 5.14% | 9.65% | 4.27% | 4.50% | 2.38% | -10.12% | -10.15% | 2.67% | -6.65% | -1.84% | 77.89% | 65.04% | 8.01% | 10.91% | -38.63% | |||||||||||||||||||||||||||||||||||||||||||||||||||
qoq | -11.42% | 11.66% | -13.97% | 19.23% | -6.93% | 9.26% | -13.28% | 3.91% | -13.10% | 15.92% | -2.19% | -8.78% | -13.13% | 32.47% | -11.07% | -4.08% | 57.42% | 22.90% | -41.80% | -1.51% | -12.90% | |||||||||||||||||||||||||||||||||||||||||||||||||
gross margin % | 18.70% | 21.09% | NaN% | 18.03% | 17.34% | 20.25% | 18.24% | 19.71% | 18.62% | 21.26% | NaN% | 19.71% | 19.19% | 21.91% | 20.19% | 20.94% | 23.67% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% |
corporate office costs | 17,414,000 | 17,476,000 | 16,245,000 | 15,571,000 | 14,385,000 | 14,249,000 | 14,085,000 | 13,901,000 | 12,048,000 | 12,145,000 | 11,925,000 | 11,889,000 | 10,741,000 | 11,556,000 | 10,718,000 | 12,867,000 | 12,074,000 | 10,874,000 | 10,916,000 | 10,422,000 | 9,022,000 | 11,677,000 | 11,673,000 | 10,556,000 | 11,527,000 | 10,306,000 | 6,923,000 | 7,468,000 | 7,614,000 | 7,132,000 | 6,766,000 | 6,224,000 | 6,622,000 | 6,507,000 | 6,507,000 | 6,147,000 | 5,977,000 | 6,396,000 | 6,262,000 | 4,407,500 | 5,142,000 | 6,007,000 | 6,481,000 | 5,709,000 | 5,798,000 | 5,511,000 | 5,805,000 | 6,430,000 | 5,790,000 | 6,234,000 | 5,388,000 | 5,052,000 | 4,677,000 | 5,431,000 | 5,062,000 | 4,624,000 | 4,209,000 | 4,136,000 | 4,357,000 | 4,515,000 | ||||||||||
loss on change in fair value of contingent earn-out consideration | -5,872,000 | -790,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income | 25,330,000 | 24,938,000 | 14,538,000 | 14,746,000 | 19,613,000 | 14,316,000 | -880,000 | 15,881,000 | 20,062,000 | 6,794,000 | 14,895,000 | 20,080,000 | 15,032,000 | 16,465,000 | 16,932,000 | 22,230,000 | 15,022,000 | 18,202,000 | 19,935,000 | 10,262,000 | 4,014,000 | 15,286,000 | 16,816,000 | 19,898,000 | 14,850,000 | 11,949,000 | 10,684,000 | 8,151,000 | 8,151,000 | 7,942,000 | 9,392,000 | 10,598,000 | 9,871,000 | 7,054,000 | 8,652,000 | 10,882,000 | 8,682,000 | 7,801,000 | 8,733,000 | 9,990,000 | 6,666,000 | 6,113,000 | 7,195,000 | 8,487,000 | 6,457,000 | 3,550,000 | ||||||||||||||||||||||||
yoy | 71.78% | 27.15% | -1752.05% | -7.15% | -2.24% | -112.95% | 6.62% | -0.09% | -58.74% | -12.03% | -9.67% | 0.07% | -9.54% | -15.06% | 116.62% | 274.24% | 19.08% | 18.55% | -48.43% | 13.76% | -23.09% | -17.42% | 12.59% | 8.55% | -2.61% | 13.70% | -9.58% | -0.93% | 8.93% | 30.24% | 27.61% | 21.38% | 17.71% | 3.24% | ||||||||||||||||||||||||||||||||||||
qoq | 1.57% | -1.41% | -24.82% | 37.00% | -1726.82% | -105.54% | -20.84% | -54.39% | -25.82% | 33.58% | -8.70% | -2.76% | -23.83% | 47.98% | -17.47% | -8.69% | 94.26% | 155.66% | -73.74% | -9.10% | -15.49% | 24.28% | 31.08% | 0.00% | 2.63% | -15.44% | -11.38% | 7.37% | 39.93% | -18.47% | -20.49% | 25.34% | 11.29% | -10.67% | -12.58% | 49.86% | 9.05% | -15.04% | -15.22% | 31.44% | ||||||||||||||||||||||||||||||
operating margin % | 12.85% | 12.64% | NaN% | 8.06% | 8.78% | 11.73% | 9.20% | -0.57% | 10.59% | 13.24% | NaN% | 4.81% | 10.67% | 14.28% | 11.41% | 12.68% | 13.45% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | Infinity% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | Infinity% |
other income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense, debt and other | -2,408,000 | -2,422,000 | 2,279,000 | -2,049,000 | -2,018,000 | -1,980,000 | -1,968,000 | -2,010,000 | -2,101,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income from investments | 33,000 | 28,000 | -24,000 | 306,000 | 1,018,000 | 1,074,000 | 1,543,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in revaluation of put-right liability | -663,000 | -339,000 | 404,000 | 54,000 | 168,000 | -223,000 | -80,000 | 2,926,000 | -145,000 | -50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity in earnings of unconsolidated affiliate | 361,000 | 401,000 | -393,000 | 264,000 | 231,000 | 248,000 | 271,000 | 149,000 | 206,000 | 326,000 | 192,000 | 304,000 | 340,000 | 339,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of a partnership | 123,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other | 222,000 | 47,000 | -75,000 | 96,000 | 90,000 | 109,000 | 62,000 | 85,000 | 78,000 | -54,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other expense | -2,455,000 | -2,285,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before taxes | 22,875,000 | 22,653,000 | 17,328,000 | 18,322,000 | 12,336,000 | 14,795,000 | 14,756,000 | 106,000 | 15,779,000 | 19,095,000 | 4,560,000 | 16,036,000 | 19,495,000 | 15,480,000 | 13,701,750 | 17,938,000 | 22,039,000 | 14,830,000 | 23,196,000 | 20,042,000 | 18,645,000 | 3,630,000 | 14,439,000 | 16,266,000 | 25,118,000 | 4,182,000 | 11,718,000 | 10,555,000 | 7,354,000 | 9,251,000 | 10,454,000 | 9,711,000 | 6,973,250 | 8,507,000 | 10,775,000 | 8,611,000 | 6,444,250 | 8,684,000 | 9,911,000 | 7,182,000 | ||||||||||||||||||||||||||||||
provision for income taxes | 5,233,000 | 4,933,000 | 5,828,000 | 2,559,000 | 3,083,000 | 1,399,000 | 3,557,000 | 4,231,000 | 1,212,000 | 3,215,000 | 4,239,000 | 3,498,000 | 3,946,000 | 3,815,000 | 4,567,000 | 2,944,000 | 4,569,000 | 4,279,000 | 3,882,000 | 292,000 | 2,424,000 | 3,197,000 | 5,318,000 | 3,172,000 | 2,426,000 | |||||||||||||||||||||||||||||||||||||||||||||
net income | 17,642,000 | 17,720,000 | 12,494,000 | 9,777,000 | 11,712,000 | 11,617,000 | -1,293,000 | 12,222,000 | 14,864,000 | 3,348,000 | 12,821,000 | 15,256,000 | 11,982,000 | 14,443,000 | 14,123,000 | 17,472,000 | 11,886,000 | 18,627,000 | 15,763,000 | 14,763,000 | 3,338,000 | 12,015,000 | 13,069,000 | 19,800,000 | 2,233,000 | 2,531,000 | 2,855,000 | 2,385,000 | 2,486,000 | 2,120,000 | 2,303,000 | 1,829,000 | 1,484,000 | |||||||||||||||||||||||||||||||||||||
yoy | 80.44% | 51.30% | -1066.28% | -20.00% | -21.21% | -138.62% | -4.67% | -2.57% | -76.82% | -9.22% | -12.68% | 0.81% | -22.46% | -10.40% | 18.35% | 256.08% | 55.03% | 20.61% | -25.44% | -10.18% | 19.39% | 23.97% | 30.40% | 42.86% | ||||||||||||||||||||||||||||||||||||||||||||||
qoq | -0.44% | 27.79% | -16.52% | 0.82% | -998.45% | -110.58% | -17.77% | -73.89% | -15.96% | 27.32% | -17.04% | 2.27% | -19.17% | 47.00% | -36.19% | 18.17% | 6.77% | 342.27% | -72.22% | -8.06% | -33.99% | -11.77% | -11.35% | 19.71% | -4.06% | 17.26% | -7.95% | 25.92% | ||||||||||||||||||||||||||||||||||||||||||
net income margin % | 8.95% | 8.98% | NaN% | 6.92% | 5.82% | 7.01% | 7.46% | -0.84% | 8.15% | 9.81% | NaN% | 2.37% | 9.18% | 10.85% | 9.10% | 11.12% | 11.22% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | Infinity% | NaN% | Infinity% |
less: net income attributable to non-controlling interest: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interest - temporary equity | -3,790,000 | -3,914,000 | -2,505,000 | -1,998,000 | -3,314,000 | -2,227,000 | 3,190,000 | -1,976,000 | -2,920,000 | 318,000 | -2,037,000 | -2,626,000 | -2,557,000 | -2,689,000 | -2,605,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interest - permanent equity | -714,000 | -1,413,000 | -745,000 | -1,151,000 | -892,000 | -1,344,000 | -1,241,000 | -992,000 | -1,025,000 | -1,059,000 | -1,227,000 | -1,435,000 | -626,000 | -1,541,000 | -1,509,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to usph shareholders | 13,138,000 | 12,393,000 | 9,244,000 | 6,628,000 | 7,506,000 | 8,046,000 | 656,000 | 9,254,000 | 10,919,000 | 2,607,000 | 9,557,000 | 11,195,000 | 8,799,000 | 10,213,000 | 10,009,000 | 12,436,000 | 8,173,000 | 13,030,000 | 10,916,000 | 10,232,000 | 1,016,000 | 7,929,000 | 9,047,000 | 14,620,000 | 8,443 | 34,848,535 | 8,102 | 9,246 | 7,117 | 5,150 | 4,941 | |||||||||||||||||||||||||||||||||||||||
basic and diluted earnings per share attributable to usph shareholders | 0.48 | 0.58 | 0.52 | 0.39 | 0.47 | 0.46 | -0.44 | 0.51 | 0.64 | -0.02 | 0.72 | 0.87 | 0.67 | 0.72 | 0.66 | 0.82 | 0.21 | 0.68 | 0.61 | 0.99 | 0.2 | 0.55 | 0.66 | 0.85 | ||||||||||||||||||||||||||||||||||||||||||||||
shares used in computation - basic and diluted | 15,204 | 15,197 | 9 | 15,077 | 15,072 | 15,017 | 270 | 14,987 | 13,720 | 6 | 13,001 | 12,998 | 12,937 | 4 | 12,909 | 12,902 | 12,870 | 6 | 12,847 | 12,843 | 12,796 | 6 | 12,774 | 12,767 | ||||||||||||||||||||||||||||||||||||||||||||||
dividends declared per common share | 0.45 | 0.45 | 0.44 | 0.44 | 0.44 | 0.44 | 0.43 | 0.43 | 0.43 | 0.41 | 0.41 | 0.41 | 0.41 | 0.38 | 0.38 | 0.35 | 0.35 | 0.32 | 0.3 | 0.3 | 0.27 | 0.23 | 0.15 | 0.12 | 0.12 | 0.12 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.49 | 0.09 | 0.09 | 0.09 | 0.06 | 0.08 | 0.08 | 0.08 | |||||||||||||||||||||||||||||||
clinic closure costs - lease and other | 69,000 | 246,000 | 3,432,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average remaining lease term | 4,490 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average discount rate | 4,800 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
physical therapy operations | 156,408,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
industrial injury prevention services | 27,380,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total company | 183,788,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating costs: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
salaries and related costs: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total salaries and related costs | 111,249,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rent supplies, contract labor and other: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total rent, supplies, contract labor and other | 33,844,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total depreciation and amortization | 5,540,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provision for credit losses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total provision for credit losses | 1,848,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
clinic closure costs: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total clinic closure costs | 242,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gross profit: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unallocated amounts | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on change in fair value of contingent earn-out consideration | -4,822,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total unallocated amounts | 13,737,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total goodwil | 674,387,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
all other assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total all other assets | 505,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total assets | 1,179,687,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of contingent earn-out consideration | 5,113,000 | -1,899,000 | -4,046,000 | 612,000 | -1,747,000 | 187,000 | 708,000 | 520,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
relief funds | 5,152,000 | 390,000 | 7,959,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other income | -1,697,000 | -2,410,000 | -4,818,000 | 440,000 | 986,000 | -102,000 | -967,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
benefit from credit losses | 1,627,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
benefit from income taxes | 3,139,000 | 2,658,500 | 3,654,000 | 3,625,000 | 4,469,000 | 2,939,000 | 3,438,000 | 3,017,000 | 3,181,000 | 2,409,000 | 2,409,000 | 2,042,000 | 2,953,000 | 3,140,000 | 2,899,000 | 2,063,000 | 2,654,000 | 1,858,750 | 2,507,000 | 2,877,000 | 2,051,000 | 1,849,000 | 1,964,000 | 2,342,000 | 1,779,000 | 1,263,500 | 1,635,000 | 1,863,000 | 1,556,000 | 1,534,000 | 1,297,000 | 1,465,000 | 1,169,000 | 926,000 | ||||||||||||||||||||||||||||||||||||
other income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 547,750 | 1,673,000 | 3,000 | 82,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense - debt and other | -2,633,000 | -2,239,000 | -2,013,000 | -987,000 | -540,000 | -191,000 | -268,000 | -237,000 | -246,000 | -203,000 | -351,000 | -653,000 | -427,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other and interest income | 682,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
november 2022 acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
october 2022 acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
september 2022 acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
august 2022 acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
march 2022 acquisition | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjusted ebitda | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity-based awards compensation expense | 222,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
allocation to non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
computation of earnings per share - usph shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charges to retained earnings: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revaluation of redeemable non-controlling interest | -4,661 | -4,526.25 | -8,680 | -4,344 | -5,081 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax effect at statutory rate | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating results | 6,004 | 7,432 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted operating results per share | 0.48 | 0.59 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income and expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
resolution of a payor matter | 1,216,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest and other income | 69,000 | 65,000 | 679,000 | 46,000 | 41,000 | 58,000 | 46,000 | 54,000 | 45,000 | 50,000 | 4,000 | 43,000 | 19,000 | 7,000 | 4,000 | 45,000 | 24,000 | 2,000 | 1,000 | 2,000 | 2,000 | 1,000 | 2,000 | 2,000 | 2,000 | 1,000 | 1,000 | 2,000 | 2,000 | 4,000 | 2,000 | 2,000 | 3,000 | 1,000 | 2,000 | 580,000 | 1,000 | 2,000 | 2,000 | |||||||||||||||||||||||||||||||
gain on revaluation of put-right liability | 192,750 | 785,000 | 603,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other income and expense | -2,234,000 | 1,141,000 | -585,000 | 448,000 | 1,924,000 | 1,006,000 | -191,000 | -192,000 | 4,994,000 | 107,000 | 8,383,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on revaluation of put-right liability | -617,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to non-controlling interest: - sum | -4,061,000 | -3,183,000 | -4,230,000 | -4,114,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
closure costs - lease and other | 10,000 | 5,000 | -22,000 | 37,000 | 6,000 | 79,000 | 94,000 | 1,893,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
closure costs - derecognition of goodwill | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income and expense: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of partnership interest and clinics | 18,000 | 1,073,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net patient revenues | 113,238,000 | 99,254,000 | 104,537,000 | 96,398,000 | 72,279,000 | 100,126,000 | 108,940,000 | 104,392,000 | 113,363,000 | 106,650,000 | 417,393,105 | 103,354 | 105,989 | 93,654 | 109,427,000 | 82,154,000 | 76,184,000 | 76,470,000 | 68,397,000 | 67,256,000 | 64,368,000 | 65,295,000 | 61,505,000 | 61,505,000 | 61,110,000 | 60,782,000 | 62,052,000 | 60,499,000 | -167,828,128 | 57,332,000 | 56,678,000 | 53,872,000 | 51,278,000 | 51,748,000 | 52,296,000 | 48,779,000 | 48,789,000 | 49,578,000 | 50,291,000 | 46,664,000 | 46,409,000 | 46,128,000 | 46,205,000 | 44,197,000 | 43,084,000 | 36,906,000 | 35,171,000 | 34,276,000 | 34,061,000 | |||||||||||||||||||||
other revenues | 13,690,000 | 13,114,000 | 12,929,000 | 12,531,000 | 11,578,000 | 12,591,000 | 13,174,000 | 12,859,000 | 13,010,000 | 535,000 | 36,206,059 | 565 | 675 | 548 | 2,541,000 | 1,895,000 | 1,532,000 | 1,731,000 | 1,370,000 | 1,349,000 | 1,461,000 | 1,929,000 | 1,593,000 | 1,593,000 | 1,584,000 | 2,071,000 | 1,907,000 | 2,083,000 | 2,111,500 | 2,343,000 | 3,234,000 | 2,869,000 | 215,000 | 59,000 | 4,000 | 26,000 | 26,000 | |||||||||||||||||||||||||||||||||
net revenues | 126,928,000 | 112,368,000 | 117,466,000 | 108,929,000 | 83,857,000 | 112,717,000 | 122,114,000 | 117,251,000 | 126,373,000 | 111,968,000 | 84,049,000 | 77,716,000 | 78,201,000 | 69,767,000 | 68,605,000 | 65,829,000 | 67,224,000 | 63,098,000 | 63,098,000 | 62,694,000 | 62,853,000 | 63,959,000 | 62,582,000 | -176,271,259 | 59,675,000 | 59,912,000 | 56,741,000 | 53,327,000 | 53,398,000 | 54,103,000 | 50,405,000 | 50,416,000 | 51,037,000 | 51,787,000 | 48,169,000 | 47,814,000 | 47,232,000 | 47,389,000 | 45,251,000 | 44,154,000 | 37,453,000 | 35,459,000 | 34,620,000 | 34,656,000 | ||||||||||||||||||||||||||
total operating costs | 92,624,000 | 86,472,000 | 88,348,000 | 78,572,000 | 64,573,000 | 97,026,000 | 95,155,000 | 89,879,000 | 94,948,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to non-controlling interests: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interests - temporary equity | -3,611,000 | -2,453,000 | -3,364,000 | -3,019,000 | -2,996,000 | -1,796,000 | -2,507,000 | -2,379,000 | -3,378,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests - permanent equity | -1,425,000 | -1,260,000 | -2,233,000 | -1,828,000 | -1,535,000 | -526,000 | -1,579,000 | -1,643,000 | -1,802,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to non-controlling interests: - sum | -5,036,000 | -3,713,000 | -5,597,000 | -4,847,000 | -4,531,000 | -2,322,000 | -3,283,500 | -4,022,000 | -5,180,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provision for doubtful accounts | 844,750 | 1,279,000 | 739,000 | 1,361,000 | 1,450,000 | 962,000 | 1,240,000 | 504,000 | 624,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
closure costs - write-off of goodwill | 1,859,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
closure costs | 13,000 | 3,000 | 13,000 | 6,000 | 88,000 | -39,000 | -2,000 | 13,000 | 225,000 | -5,000 | 8,000 | 18,000 | 18,000 | 135,000 | 5,000 | 22,000 | 49,000 | 11,000 | 13,000 | 11,000 | 20,000 | 129,000 | 19,000 | -14,000 | 29,000 | 8,000 | 49,000 | 32,000 | 2,000 | 22,000 | ||||||||||||||||||||||||||||||||||||||||
gain on sale of partnership interest | -309,000 | 5,823,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense | -380,500 | -557,000 | -607,000 | -191,250 | -255,000 | -237,000 | -332,000 | -253,000 | -140,000 | -133,000 | -130,000 | -135,000 | -135,000 | -108,000 | -142,000 | -145,000 | -162,000 | -82,750 | -149,000 | -109,000 | -73,000 | -41,000 | -50,000 | -81,000 | -64,000 | -58,000 | -93,000 | -113,000 | -88,000 | -121,000 | -158,000 | -114,000 | -149,000 | -166,000 | -84,000 | |||||||||||||||||||||||||||||||||||
management contract revenues | 2,146,000 | 1,579.75 | 1,922 | 2,160 | 1,857 | 855,000 | 488,000 | 284,000 | 318,000 | 569,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
industrial injury prevention services revenues | 6,900,000 | 4,601.75 | 7,281 | 6,274 | 1,506 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax effect at statutory rate (federal and state) of 26.25% | 1,224 | 1,188.25 | 2,279 | 1,140 | 1,334 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted per share | 0.39 | 0.22 | 0.13 | 0.48 | 0.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shares used in computation: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted earnings per share - weighted-average shares | 12,707 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
computation of earnings per share - usph shareholders | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shares used in computation: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 3,165 | 12,685 | 12,677 | 12,581 | 12,579 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense mrnci * - change in redemption value | 1,247 | 3,923 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
costs related to restatement of financials - legal and accounting | 158 | 177 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax effect at statutory rate (federal and state) of 39.25% | -551 | -1,609 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted net income attributable to usph shareholders per share | 0.41 | 0.39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
· | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
clinic operating costs: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
rent, clinic supplies, contract labor and other | 21,434,000 | 17,428,000 | 16,117,000 | 15,205,000 | 14,216,000 | 14,726,000 | 12,878,000 | 12,904,000 | 12,918,000 | 12,918,000 | 13,300,000 | 12,844,000 | 12,992,000 | 12,484,000 | 8,673,750 | 12,012,000 | 11,388,000 | 11,295,000 | 10,444,000 | 10,162,000 | 10,238,000 | 10,100,000 | 10,012,000 | 10,179,000 | 9,735,000 | 10,213,000 | 10,153,000 | 10,216,000 | 9,842,000 | 9,603,000 | 9,344,000 | 8,179,000 | 7,629,000 | 7,429,000 | 7,524,000 | |||||||||||||||||||||||||||||||||||
benefit from doubtful accounts | 779,750 | 1,067,000 | 1,090,000 | 1,054,000 | 950,000 | 994,000 | 1,095,000 | 1,193,000 | 1,089,000 | 1,089,000 | 1,192,000 | 1,259,000 | 1,280,000 | 1,117,000 | 638,500 | 1,426,000 | 615,750 | 695,000 | 734,000 | 1,034,000 | 772,000 | 1,001,000 | 869,000 | 706,000 | 557,500 | 747,000 | 735,000 | 748,000 | 825,000 | 691,000 | 406,000 | 631,000 | 566,000 | |||||||||||||||||||||||||||||||||||||
total clinic operating costs | 86,812,000 | 65,177,000 | 58,970,000 | 56,366,000 | 53,121,000 | 52,467,000 | 49,701,000 | 49,918,000 | 48,440,000 | 48,440,000 | 48,605,000 | 47,484,000 | 46,965,000 | 46,449,000 | 32,620,500 | 45,881,000 | 43,023,000 | 41,578,000 | 39,817,000 | 38,867,000 | 38,602,000 | 37,934,000 | 37,873,000 | 38,052,000 | ||||||||||||||||||||||||||||||||||||||||||||||
gross margin | 25,156,000 | 18,872,000 | 18,746,000 | 21,835,000 | 16,646,000 | 16,138,000 | 16,128,000 | 17,306,000 | 14,658,000 | 14,658,000 | 14,089,000 | 15,369,000 | 16,994,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income including non-controlling interests | 5,833,000 | 8,064,000 | 7,418,000 | 9,420,000 | 6,323,000 | 5,754,000 | 2,259,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to non-controlling interests | 1,327,000 | -2,246,000 | -2,202,000 | -2,988,000 | -2,095,000 | -1,893,000 | -2,032,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to common shareholders | 4,072,000 | 5,818,000 | 5,216,000 | 6,432,000 | 4,228,000 | 3,861,000 | 227,000 | 4,914,000 | 3,721,000 | 3,721,000 | 4,043,000 | 4,563,000 | 4,849,000 | 4,478,000 | 8,229,000 | 4,099,000 | 4,900,000 | 3,746,000 | 4,147,000 | 3,875,000 | 4,451,000 | 3,172,000 | 2,290,000 | 3,101,000 | ||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per share attributable to common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
from operations prior to revaluation of redeemable non-controlling interests, net of tax | 0.33 | 0.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charges to additional paid-in-capital - revaluation of redeemable non-controlling interests, net of tax | -0.008 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.323 | 0.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share attributable to common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 0.323 | 0.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shares used in computation: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 3,095.5 | 12,421 | 12,244 | 12,224 | 12,129 | 13 | 12,106 | 12,089 | 11,955 | 11,955 | 26 | 11,827 | 11,781 | 11,726 | -106 | 11,886 | 11,807 | 11,718 | 4 | 11,667 | 11,622 | 11,614 | -31 | 11,570 | 11,615 | 12,020 | ||||||||||||||||||||||||||||||||||||||||||||
diluted | 3,095.5 | 12,421 | 12,247 | 12,226 | 12,144 | 13 | 12,120 | 12,110 | 11,979 | 11,979 | 12 | 11,928 | 11,903 | 11,838 | -62 | 12,011 | 11,999 | 11,945 | 8 | 11,889 | 11,857 | 11,840 | 26 | 11,748 | 11,653 | 12,025 | ||||||||||||||||||||||||||||||||||||||||||||
operating income from continuing operations | 11,278,000 | 14,221,000 | 9,514,000 | 9,372,000 | 9,904,000 | 5,648,000 | 5,931,000 | 6,560,000 | 5,737,000 | 5,737,000 | 4,795,000 | 5,216,000 | 4,287,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before taxes from continuing operations | 11,043,000 | 13,889,000 | 9,262,000 | 9,234,000 | 9,773,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations including non-controlling interests | 7,418,000 | 9,420,000 | 6,323,000 | 5,796,000 | 6,756,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
discontinued operations, net of tax | -1,241,250 | -4,497,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share attributable to common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
from continuing operations | 0.43 | 0.53 | 0.35 | 0.32 | 0.38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revaluation of redeemable non-controlling interests, net of tax | -0.01 | -0.08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
from discontinued operations | -0.01 | -0.36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.43 | 0.52 | 0.31 | 0.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 0.43 | 0.52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings attributable to common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
from discontinued operations | -0.01 | -0.36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
from discontinued operations | -0.01 | -0.36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.43 | 0.52 | 0.31 | 0.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per share attributable to common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 0.32 | 0.02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income including noncontrolling interests | 7,374,000 | 5,609,000 | 5,609,000 | 5,794,000 | 6,298,000 | 7,314,000 | 6,812,000 | -19,634,815 | 5,853,000 | 7,603,000 | 6,185,000 | 6,358,000 | 6,177,000 | 7,034,000 | 5,131,000 | 4,207,000 | 5,140,000 | 6,034,000 | 4,593,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to noncontrolling interests | -2,460,000 | -1,888,000 | -1,888,000 | -1,751,000 | -1,735,000 | -2,465,000 | -2,334,000 | -1,724,000 | -1,754,000 | -2,703,000 | -2,439,000 | -2,211,000 | -2,302,000 | -2,583,000 | -1,959,000 | -1,917,000 | -2,039,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.41 | 0.31 | 0.31 | 0.34 | 0.39 | 0.41 | 0.38 | 0.27 | 0.35 | 0.42 | 0.32 | 0.35 | 0.33 | 0.38 | 0.27 | 0.203 | 0.27 | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 0.41 | 0.31 | 0.31 | 0.34 | 0.38 | 0.41 | 0.38 | 0.265 | 0.34 | 0.41 | 0.31 | 0.35 | 0.33 | 0.38 | 0.27 | 0.2 | 0.26 | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
income from operations | 8,018,000 | 8,018,000 | 6,056,000 | 7,104,000 | 8,376,000 | 6,372,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
management contract revenues and other revenues | 2,049,000 | 1,650,000 | 1,807,000 | 1,626,000 | 1,627,000 | 1,459,000 | 1,496,000 | 1,505,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: net income attributable to noncontrolling interest | -2,412,000 | -1,839,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to u. s. physical therapy, inc | 3,622,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share attributable to u. s. physical therapy, inc. common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.41 | 0.31 | 0.31 | 0.34 | 0.39 | 0.41 | 0.38 | 0.27 | 0.35 | 0.42 | 0.32 | 0.35 | 0.33 | 0.38 | 0.27 | 0.203 | 0.27 | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 0.41 | 0.31 | 0.31 | 0.34 | 0.38 | 0.41 | 0.38 | 0.265 | 0.34 | 0.41 | 0.31 | 0.35 | 0.33 | 0.38 | 0.27 | 0.2 | 0.26 | 0.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to u. s. physical therapy, inc. | 2,754,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income attributable to u. s. physical therapy, inc. common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted | 0.23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
management contract and other revenues | 835,500 | 1,104,000 | 1,184,000 | 1,054,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest, investment and other income | 10,000 | -24,000 | 249,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interests in subsidiary limited partnerships | -1,853,000 | -1,583,000 | -1,977,000 | -1,672,000 | -1,576,000 | -1,369,000 | -1,467,000 | -1,315,000 | -1,201,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before income taxes from continuing operations | 3,684,000 | 4,166,000 | 4,718,000 | 3,941,000 | 4,016,000 | 3,429,000 | 3,822,000 | 3,013,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations | 2,233,000 | 2,531,000 | 2,855,000 | 2,385,000 | 2,482,000 | 2,132,000 | 2,357,000 | 1,844,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
discontinued operations: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from discontinued operations | 6,000 | -17,000 | -86,000 | -24,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit (expense) from discontinued operations | -2,000 | 5,000 | 32,000 | 9,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic — income from continuing operations | 0.19 | 0.21 | 0.24 | 0.2 | 0.21 | 0.18 | 0.2 | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic — income from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total basic earnings per common share | 0.19 | 0.21 | 0.24 | 0.2 | 0.21 | 0.18 | 0.2 | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted — income from continuing operations | 0.18 | 0.21 | 0.24 | 0.2 | 0.21 | 0.18 | 0.2 | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted — income from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total diluted earnings per common share | 0.18 | 0.21 | 0.24 | 0.2 | 0.21 | 0.18 | 0.2 | 0.16 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per common share | 26 | 11,918 | 11,874 | 11,852 | 65 | 11,673 | 11,559 | 11,501 | 130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per common share | 12 | 12,132 | 12,045 | 11,914 | 61 | 11,738 | 11,648 | 11,589 | 120 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest and investment income | 25,000 | 21,000 | 87,000 | 73,000 | 41,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(loss) from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss in unconsolidated joint venture | -21,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale or disposal of fixed assets | 12,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before income taxes | 2,410,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash provided by | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interests in earnings of subsidiary limited partnerships | 1,201,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | 471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale or abandonment of fixed assets | 12,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from exercise of stock options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
recognition of deferred rent subsidies | -103,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in patient accounts receivable | -1,218,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable -- other | -137,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in other assets | -107,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts payable and accrued expenses | 1,313,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in other liabilities | 187,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities | 4,981,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of fixed assets | -1,480,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of minority interests, included in goodwill | -800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities | -2,334,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions to minority investors in subsidiary limited partnerships | -881,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repurchase of common stock | -860,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of notes payable | -68,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from stock options exercised | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of stock options | 11,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from financing activities | -1,788,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | 859,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents -- beginning of period | 15,002,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents - end of period | 15,861,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the period for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes | 256,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | 11,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2013-03-13 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-03-31 | 2005-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 28,439,000 | 35,570,000 | 31,102,000 | 34,086,000 | 39,183,000 | 41,362,000 | 116,959,000 | 112,911,000 | 132,290,000 | 152,825,000 | 147,685,000 | 160,738,000 | 32,605,000 | 31,594,000 | 37,914,000 | 48,572,000 | 24,229,000 | 28,567,000 | 19,188,000 | 20,419,000 | 17,937,000 | 32,918,000 | 30,129,000 | 43,555,000 | 89,551,000 | 23,548,000 | 27,856,000 | 34,859,000 | 20,238,000 | 23,368,000 | 32,241,000 | 27,148,000 | 19,813,000 | 21,933,000 | 17,418,000 | 20,242,000 | 25,154,000 | 20,047,000 | 15,024,000 | 20,453,000 | 19,206,000 | 20,558,000 | 12,972,000 | 14,557,000 | 14,271,000 | 15,824,000 | 12,934,000 | 16,761,000 | 12,898,000 | 12,123,000 | 10,287,000 | 10,284,000 | 10,284,000 | 11,671,000 | 9,983,000 | 9,179,000 | 6,429,000 | 9,326,000 | 10,439,000 | 11,081,000 | 10,113,000 | 9,153,000 | 8,073,000 | 9,197,000 | 7,976,000 | 9,566,000 | 11,968,000 | 13,093,000 | 10,952,000 | 15,861,000 | 15,002,000 | |||||||||
patient accounts receivable, less provision for credit losses of 3,902 and 3,775, respectively | 69,082,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other | 27,642,000 | 24,087,000 | 23,672,000 | 27,429,000 | 26,136,000 | 26,626,000 | 20,056,000 | 21,669,000 | 21,774,000 | 17,854,000 | 18,469,000 | 16,852,000 | 17,816,000 | 16,671,000 | 19,146,000 | 18,915,000 | 18,239,000 | 16,144,000 | 10,093,000 | 9,025,000 | 8,621,000 | 9,039,000 | 9,878,000 | 9,983,000 | 11,650,000 | 9,823,000 | 10,462,000 | 10,724,000 | 7,237,000 | 6,742,000 | 9,609,000 | 8,589,000 | 6,504,000 | 5,655,000 | 6,992,000 | 5,662,000 | 6,346,000 | |||||||||||||||||||||||||||||||||||||||||||
other current assets | 13,946,000 | 16,084,000 | 16,032,000 | 13,061,000 | 15,274,000 | 10,555,000 | 10,833,000 | 12,438,000 | 11,715,000 | 10,830,000 | 9,387,000 | 9,924,000 | 10,726,000 | 11,067,000 | 6,085,000 | 3,810,000 | 4,040,000 | 4,183,000 | 3,687,000 | 5,111,000 | 3,846,000 | 3,773,000 | 3,198,000 | 2,572,000 | 4,822,000 | 5,787,000 | 7,098,000 | 7,102,000 | 5,238,000 | 4,353,000 | 4,908,000 | 5,247,000 | 3,050,000 | 4,786,000 | 5,444,000 | 6,932,000 | 3,827,000 | 4,428,000 | 10,800,000 | 8,220,000 | 8,298,000 | 6,058,000 | 6,509,000 | 5,291,000 | 6,186,000 | 5,076,000 | 2,703,000 | 3,040,000 | 4,098,000 | 4,482,000 | 1,878,000 | 3,862,000 | 3,862,000 | 5,975,000 | 4,956,000 | 5,328,000 | 5,248,000 | 5,737,000 | 6,232,000 | 5,179,000 | 3,466,000 | 3,736,000 | 2,944,000 | 3,356,000 | 2,124,000 | 2,959,000 | 2,260,000 | 2,103,000 | 2,334,000 | 1,857,000 | 1,752,000 | 2,098,000 | 1,509,000 | 1,333,000 | 2,173,000 | 2,031,000 | 2,067,000 | 2,251,000 | 1,692,000 | 1,428,000 |
total current assets | 139,109,000 | 139,990,000 | 138,435,000 | 140,532,000 | 145,353,000 | 137,583,000 | 204,870,000 | 201,677,000 | 221,142,000 | 233,375,000 | 228,499,000 | 241,799,000 | 117,794,000 | 111,266,000 | 112,892,000 | 121,846,000 | 95,843,000 | 95,166,000 | 79,424,000 | 79,699,000 | 75,798,000 | 87,636,000 | 82,644,000 | 92,139,000 | 148,672,000 | 85,386,000 | 92,534,000 | 107,009,000 | 81,156,000 | 79,214,000 | 90,657,000 | 86,408,000 | 75,595,000 | 77,081,000 | 73,415,000 | 79,606,000 | 78,571,000 | 65,964,000 | 66,618,000 | 70,364,000 | 68,066,000 | 63,661,000 | 55,649,000 | 55,899,000 | 54,851,000 | 56,615,000 | 51,847,000 | 54,254,000 | 49,660,000 | 45,157,000 | 41,429,000 | 44,722,000 | 44,722,000 | 45,322,000 | 44,063,000 | 44,644,000 | 47,123,000 | 45,667,000 | 45,836,000 | 44,252,000 | 44,060,000 | 39,284,000 | 38,064,000 | 35,212,000 | 39,223,000 | 33,019,000 | 36,007,000 | 36,945,000 | 39,766,000 | 38,721,000 | 38,712,000 | 39,525,000 | 39,307,000 | 36,033,000 | 38,790,000 | 39,020,000 | 39,095,000 | 35,981,000 | 38,764,000 | 36,852,000 |
fixed assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
furniture and equipment | 70,376,000 | 67,891,000 | 67,522,000 | 66,756,000 | 68,802,000 | 68,128,000 | 66,782,000 | 65,775,000 | 65,550,000 | 63,982,000 | 64,507,000 | 63,429,000 | 63,139,000 | 62,074,000 | 62,006,000 | 60,379,000 | 60,205,000 | 58,743,000 | 58,179,000 | 57,538,000 | 56,754,000 | 55,426,000 | 55,411,000 | 55,914,000 | 56,873,000 | 54,942,000 | 54,464,000 | 52,831,000 | 53,267,000 | 52,611,000 | 52,473,000 | 51,923,000 | 51,569,000 | 51,100,000 | 51,822,000 | 50,644,000 | 49,820,000 | 48,426,000 | 46,996,000 | 46,747,000 | 45,654,000 | 44,157,000 | 43,495,000 | 42,542,000 | 42,003,000 | 42,104,000 | 41,310,000 | 39,472,000 | 38,965,000 | 37,496,000 | 37,941,000 | 36,960,000 | 36,960,000 | 36,316,000 | 35,853,000 | 35,230,000 | 35,491,000 | 35,103,000 | 35,024,000 | 33,953,000 | 33,943,000 | 33,563,000 | 32,491,000 | 32,220,000 | 32,154,000 | 31,973,000 | 32,207,000 | 32,121,000 | 32,150,000 | 30,947,000 | 30,421,000 | 29,929,000 | 29,281,000 | 28,782,000 | 28,124,000 | 24,650,000 | 24,098,000 | 23,718,000 | 23,884,000 | 23,010,000 |
leasehold improvements | 61,375,000 | 58,985,000 | 58,015,000 | 55,218,000 | 53,504,000 | 51,105,000 | 48,385,000 | 48,730,000 | 47,458,000 | 46,941,000 | 46,212,000 | 45,096,000 | 43,525,000 | 42,877,000 | 41,961,000 | 41,038,000 | 40,541,000 | 39,194,000 | 37,413,000 | 35,986,000 | 35,492,000 | 35,320,000 | 34,111,000 | 33,631,000 | 32,873,000 | 33,247,000 | 31,948,000 | 31,020,000 | 33,089,000 | 31,712,000 | 31,101,000 | 30,421,000 | 29,981,000 | 29,760,000 | 28,449,000 | 27,729,000 | 27,582,000 | 26,765,000 | 26,206,000 | 25,733,000 | 25,547,000 | 25,006,000 | 24,107,000 | 23,565,000 | 22,806,000 | 22,639,000 | 22,065,000 | 21,701,000 | 21,891,000 | 22,170,000 | 21,404,000 | 21,353,000 | 21,353,000 | 20,858,000 | 20,598,000 | 20,407,000 | 19,987,000 | 20,385,000 | 19,990,000 | 19,733,000 | 19,587,000 | 19,590,000 | 19,240,000 | 18,999,000 | 18,916,000 | 19,012,000 | 19,209,000 | 18,581,000 | 18,175,000 | 18,061,000 | 17,792,000 | 17,512,000 | 17,068,000 | 17,352,000 | 17,325,000 | 16,171,000 | 15,554,000 | 15,226,000 | 14,835,000 | 14,556,000 |
fixed assets, gross | 131,751,000 | 126,876,000 | 125,537,000 | 121,974,000 | 122,306,000 | 119,233,000 | 115,167,000 | 114,505,000 | 113,008,000 | 110,923,000 | 110,719,000 | 108,525,000 | 106,664,000 | 104,951,000 | 103,967,000 | 101,417,000 | 100,746,000 | 97,937,000 | 95,592,000 | 93,524,000 | 92,246,000 | 90,746,000 | 89,522,000 | 89,545,000 | 89,746,000 | 88,189,000 | 86,412,000 | 83,851,000 | 86,356,000 | 84,323,000 | 83,574,000 | 82,344,000 | 81,550,000 | 80,860,000 | 80,271,000 | 78,373,000 | 77,402,000 | 75,191,000 | 73,202,000 | 72,480,000 | 71,201,000 | 64,809,000 | ||||||||||||||||||||||||||||||||||||||
less accumulated depreciation and amortization | -93,129,000 | -91,225,000 | -91,315,000 | -89,853,000 | -89,542,000 | -87,093,000 | -88,602,000 | -88,277,000 | -86,757,000 | -84,821,000 | 84,651,000 | 83,548,000 | 82,026,000 | 80,203,000 | 78,960,000 | 77,188,000 | 76,601,000 | 74,958,000 | 73,556,000 | 71,964,000 | 70,485,000 | 69,081,000 | 68,048,000 | 67,011,000 | 66,764,000 | 66,099,000 | 65,040,000 | 63,829,000 | 65,197,000 | 64,154,000 | 63,608,000 | 62,652,000 | 61,742,000 | 60,475,000 | 59,517,000 | 58,200,000 | 57,235,000 | 56,018,000 | 55,760,000 | 55,642,000 | 54,512,000 | 52,501,000 | 51,098,000 | 50,212,000 | 49,045,000 | 48,685,000 | 47,517,000 | 46,543,000 | 45,896,000 | 46,150,000 | 45,588,000 | 44,922,000 | 44,922,000 | 44,158,000 | 43,634,000 | 42,747,000 | 42,556,000 | 42,299,000 | 41,432,000 | 40,940,000 | 39,998,000 | 39,230,000 | 38,546,000 | 37,816,000 | 37,185,000 | 36,646,000 | 36,314,000 | 35,131,000 | 34,105,000 | 33,167,000 | 32,106,000 | 30,893,000 | 30,086,000 | 29,342,000 | 28,373,000 | 27,628,000 | 26,618,000 | 25,573,000 | 24,591,000 | 23,825,000 |
fixed assets | 38,622,000 | 35,651,000 | 34,222,000 | 32,121,000 | 32,764,000 | 32,140,000 | 26,565,000 | 26,228,000 | 26,251,000 | 26,102,000 | 26,068,000 | 24,977,000 | 24,638,000 | 24,748,000 | 25,007,000 | 24,229,000 | 24,145,000 | 22,979,000 | 22,036,000 | 21,560,000 | 21,761,000 | 21,665,000 | 21,474,000 | 22,534,000 | 22,982,000 | 22,090,000 | 21,372,000 | 20,022,000 | 21,159,000 | 20,169,000 | 19,966,000 | 19,692,000 | 19,808,000 | 20,385,000 | 20,754,000 | 20,173,000 | 20,167,000 | 19,173,000 | 17,442,000 | 16,838,000 | 16,689,000 | 15,764,000 | ||||||||||||||||||||||||||||||||||||||
operating lease right-of-use assets | 149,202,000 | 144,197,000 | 139,926,000 | 137,248,000 | 133,197,000 | 133,936,000 | 103,938,000 | 105,484,000 | 102,113,000 | 103,431,000 | 102,665,000 | 101,582,000 | 100,604,000 | 103,004,000 | 100,967,000 | 101,274,000 | 94,243,000 | 96,427,000 | 92,952,000 | 87,090,000 | 81,553,000 | 81,595,000 | 78,784,000 | 82,965,000 | 83,619,000 | 81,586,000 | 79,793,000 | 74,930,000 | 77,870,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
investment in unconsolidated affiliate | 12,443,000 | 12,275,000 | 12,289,000 | 12,320,000 | 12,273,000 | 12,190,000 | 12,168,000 | 12,243,000 | 12,160,000 | 12,256,000 | 12,256,000 | 12,229,000 | 12,160,000 | 12,131,000 | 11,978,000 | 12,346,000 | 12,422,000 | 12,215,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill | 715,874,000 | 692,392,000 | 690,412,000 | 677,595,000 | 674,387,000 | 667,152,000 | 554,642,000 | 548,970,000 | 534,271,000 | 509,571,000 | 522,907,000 | 506,703,000 | 501,347,000 | 494,101,000 | 449,548,000 | 442,761,000 | 443,692,000 | 434,679,000 | 374,047,000 | 373,887,000 | 360,176,000 | 345,646,000 | 336,946,000 | 330,894,000 | 330,769,000 | 317,676,000 | 316,639,000 | 303,549,000 | 293,338,000 | 293,525,000 | 293,630,000 | 284,624,000 | 273,770,000 | 271,338,000 | 268,050,000 | 267,957,000 | 244,446,000 | 226,806,000 | 191,231,000 | 191,268,000 | 191,051,000 | 170,849,000 | 170,914,000 | 159,176,000 | 147,914,000 | 150,471,000 | 156,207,000 | 142,517,000 | 143,955,000 | 105,234,000 | 112,248,000 | 103,581,000 | 103,581,000 | 100,188,000 | 99,716,000 | 99,141,000 | 93,797,000 | 92,750,000 | 91,452,000 | 76,588,000 | 79,410,000 | 79,424,000 | 67,327,000 | 67,359,000 | 68,801,000 | 57,247,000 | 56,069,000 | 56,097,000 | 55,886,000 | 55,886,000 | 48,932,000 | 49,788,000 | 40,631,000 | 37,650,000 | 39,759,000 | 21,082,000 | 21,082,000 | 20,997,000 | 15,193,000 | 14,339,000 |
other identifiable intangible assets | 179,819,000 | 172,861,000 | 176,429,000 | 175,627,000 | 177,328,000 | 179,311,000 | 124,309,000 | 123,903,000 | 116,888,000 | 109,682,000 | 112,112,000 | 107,592,000 | 108,991,000 | 108,755,000 | 93,697,000 | 92,655,000 | 91,546,000 | 86,382,000 | 60,086,000 | 59,216,000 | 57,593,000 | 56,280,000 | 54,060,000 | 54,895,000 | 55,648,000 | 52,588,000 | 53,385,000 | 50,055,000 | 48,125,000 | 48,828,000 | 49,311,000 | 48,435,000 | 47,092,000 | 48,954,000 | 47,568,000 | 48,321,000 | 43,213,000 | 38,060,000 | 33,389,000 | 33,909,000 | 34,428,000 | |||||||||||||||||||||||||||||||||||||||
other assets | 6,988,000 | 6,644,000 | 4,557,000 | 4,157,000 | 4,385,000 | 5,155,000 | 2,699,000 | 4,629,000 | 4,431,000 | 2,821,000 | 5,679,000 | 4,699,000 | 2,593,000 | 4,149,000 | 5,619,000 | 1,333,000 | 1,972,000 | 1,578,000 | 1,553,000 | 1,506,000 | 1,509,000 | 1,539,000 | 1,530,000 | 1,591,000 | 1,563,000 | 1,519,000 | 1,470,000 | 1,445,000 | 1,439,000 | 1,430,000 | 1,405,000 | 1,384,000 | 1,357,000 | 1,224,000 | 1,200,000 | 1,268,000 | 1,274,000 | 1,228,000 | 1,221,000 | 1,219,000 | 1,200,000 | 1,175,000 | 1,086,000 | 1,916,000 | 1,115,000 | 1,978,000 | 1,141,000 | 1,317,000 | 1,081,000 | 1,078,000 | 967,000 | 953,000 | 953,000 | 1,042,000 | 1,018,000 | 1,435,000 | 1,079,000 | 2,043,000 | 3,396,000 | 3,303,000 | 2,206,000 | 922,000 | 930,000 | 923,000 | 885,000 | 869,000 | 855,000 | 849,000 | 834,000 | 1,347,000 | 1,770,000 | 2,094,000 | 1,476,000 | 1,847,000 | 2,777,000 | 1,585,000 | 1,591,000 | 1,108,000 | 950,000 | 1,587,000 |
total assets | 1,242,057,000 | 1,204,010,000 | 1,196,270,000 | 1,179,600,000 | 1,179,687,000 | 1,167,467,000 | 1,029,191,000 | 1,023,134,000 | 1,017,256,000 | 997,238,000 | 1,010,186,000 | 999,581,000 | 868,127,000 | 858,154,000 | 799,708,000 | 796,444,000 | 763,863,000 | 749,426,000 | 630,098,000 | 622,958,000 | 598,390,000 | 594,361,000 | 575,438,000 | 585,018,000 | 643,253,000 | 560,845,000 | 565,193,000 | 557,010,000 | 523,087,000 | 443,166,000 | 454,969,000 | 440,543,000 | 417,622,000 | 418,982,000 | 410,987,000 | 417,325,000 | 387,671,000 | 351,231,000 | 309,901,000 | 313,598,000 | 311,434,000 | 244,551,000 | ||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interest, usph shareholders’ equity and non-controlling interest | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable - trade | 6,758,000 | 6,059,000 | 7,417,000 | 4,200,000 | 6,088,000 | 5,936,000 | 6,361,000 | 4,100,000 | 4,866,000 | 3,898,000 | 4,509,000 | 3,674,000 | 4,233,000 | 3,300,000 | 4,471,000 | 3,793,000 | 3,272,000 | 3,268,000 | 1,532,000 | 1,782,000 | 1,955,000 | 1,335,000 | 1,060,000 | 1,802,000 | 2,950,000 | 2,494,000 | 2,863,000 | 2,426,000 | 1,894,000 | 2,019,000 | 2,067,000 | 1,705,000 | 1,722,000 | 2,165,000 | 1,754,000 | 1,613,000 | 1,996,000 | 1,634,000 | 2,181,000 | 1,668,000 | 2,244,000 | 1,662,000 | 1,451,000 | 2,292,000 | 1,782,000 | 1,901,000 | 1,835,000 | 1,423,000 | 1,722,000 | 1,275,000 | 1,585,000 | 1,585,000 | 1,399,000 | |||||||||||||||||||||||||||
accrued expenses | 56,960,000 | 80,982,000 | 56,901,000 | 65,436,000 | 68,326,000 | 59,513,000 | 64,506,000 | 58,056,000 | 53,749,000 | 55,344,000 | 35,846,000 | 43,338,000 | 45,220,000 | 37,413,000 | 33,784,000 | 41,246,000 | 51,121,000 | 45,705,000 | 50,267,000 | 44,720,000 | 51,671,000 | 59,746,000 | 60,236,000 | 51,325,000 | 40,645,000 | 30,855,000 | 33,573,000 | 31,346,000 | 39,237,000 | 38,493,000 | 40,128,000 | 35,367,000 | 38,342,000 | 33,342,000 | 31,492,000 | 31,235,000 | 30,820,000 | 21,756,000 | 23,216,000 | 26,273,000 | 20,684,000 | 18,287,000 | 19,446,000 | 18,178,000 | 22,839,000 | 19,081,000 | 20,112,000 | 17,147,000 | 20,625,000 | 14,779,000 | 15,298,000 | 11,661,000 | 11,661,000 | 14,116,000 | 12,672,000 | 14,200,000 | 10,656,000 | 14,082,000 | 11,349,000 | 12,734,000 | 25,283,000 | 12,744,000 | 13,450,000 | 10,429,000 | 12,559,000 | 12,459,000 | 13,479,000 | 10,810,000 | 11,552,000 | 11,752,000 | 12,179,000 | 9,328,000 | 9,065,000 | 9,071,000 | 9,535,000 | 6,440,000 | 9,031,000 | 7,007,000 | 6,774,000 | 5,150,000 |
current portion of operating lease liabilities | 42,779,000 | 42,134,000 | 41,960,000 | 41,038,000 | 40,124,000 | 39,835,000 | 34,828,000 | 35,243,000 | 34,699,000 | 35,252,000 | 34,446,000 | 31,274,000 | 33,650,000 | 33,709,000 | 32,540,000 | 32,083,000 | 30,625,000 | 30,475,000 | 29,197,000 | 27,860,000 | 27,292,000 | 27,512,000 | 26,905,000 | 29,591,000 | 26,826,000 | 26,486,000 | 25,644,000 | 22,558,000 | 26,733,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of term loan and notes payable | 10,801,000 | 9,865,000 | 8,802,000 | 8,168,000 | 9,257,000 | 10,999,000 | 9,605,000 | 9,700,000 | 9,222,000 | 7,691,000 | 7,555,000 | 7,530,000 | 7,730,000 | 7,863,000 | 7,490,000 | 4,780,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total current liabilities | 117,298,000 | 139,040,000 | 115,080,000 | 118,842,000 | 123,795,000 | 116,283,000 | 115,300,000 | 107,099,000 | 102,536,000 | 102,185,000 | 82,356,000 | 85,816,000 | 90,833,000 | 85,489,000 | 81,488,000 | 85,105,000 | 89,020,000 | 83,481,000 | 81,668,000 | 75,379,000 | 90,825,000 | 93,492,000 | 93,200,000 | 87,353,000 | 71,149,000 | 60,563,000 | 62,798,000 | 57,020,000 | 68,930,000 | 41,946,000 | 46,964,000 | 41,889,000 | 45,381,000 | 39,551,000 | 35,991,000 | 35,193,000 | 34,035,000 | 24,617,000 | 26,383,000 | 28,985,000 | 24,181,000 | 21,361,000 | 21,697,000 | 21,402,000 | 25,504,000 | 21,832,000 | 22,797,000 | 19,345,000 | 23,172,000 | 16,655,000 | 17,373,000 | 13,905,000 | 13,905,000 | 16,307,000 | 14,946,000 | 16,208,000 | 12,516,000 | 16,324,000 | 13,692,000 | 14,685,000 | 27,010,000 | 14,231,000 | 15,053,000 | 12,588,000 | 14,860,000 | 14,764,000 | 15,776,000 | 13,134,000 | 14,139,000 | 14,613,000 | 14,607,000 | 12,021,000 | 11,157,000 | 11,438,000 | 11,601,000 | 7,673,000 | 10,627,000 | 9,170,000 | 8,428,000 | 7,115,000 |
notes payable, net of current portion | 569,000 | 417,000 | 576,000 | 321,000 | 387,000 | 903,000 | 534,000 | 1,511,000 | 804,000 | 1,289,000 | 2,037,000 | 2,194,000 | 2,583,000 | 1,913,000 | 2,912,000 | 4,258,000 | 4,128,000 | 3,587,000 | 2,265,000 | 821,000 | 571,000 | 596,000 | 509,000 | 685,000 | 4,602,000 | 4,361,000 | 4,292,000 | 4,316,000 | 516,000 | 402,000 | 659,000 | 607,000 | 782,000 | 2,728,000 | 3,952,000 | 4,351,000 | ||||||||||||||||||||||||||||||||||||||||||||
revolving facility | 74,500,000 | 30,500,000 | 26,500,000 | 24,500,000 | 28,000,000 | 11,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
term loan, net of current portion and deferred financing costs | 118,971,000 | 121,677,000 | 124,384,000 | 127,093,000 | 128,851,000 | 130,627,000 | 132,382,000 | 134,188,000 | 135,945,000 | 137,702,000 | 139,459,000 | 141,266,000 | 142,098,000 | 142,918,000 | 143,778,000 | 144,631,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred taxes | 30,775,000 | 28,391,000 | 35,695,000 | 34,402,000 | 34,055,000 | 29,465,000 | 24,913,000 | 26,531,000 | 27,337,000 | 24,815,000 | 26,487,000 | 23,102,000 | 21,524,000 | 21,303,000 | 23,838,000 | 19,483,000 | 16,067,000 | 14,385,000 | 6,682,000 | 8,281,000 | 8,212,000 | 7,779,000 | 8,570,000 | 8,930,000 | 7,743,000 | 10,071,000 | 10,336,000 | 12,284,000 | 9,872,000 | 9,012,000 | 8,643,000 | 9,584,000 | 10,151,000 | 10,875,000 | 16,027,000 | 15,443,000 | 15,486,000 | 15,736,000 | 13,727,000 | 12,361,000 | 10,789,000 | |||||||||||||||||||||||||||||||||||||||
operating lease liabilities, net of current portion | 115,212,000 | 110,572,000 | 106,178,000 | 104,279,000 | 100,688,000 | 101,868,000 | 77,001,000 | 78,329,000 | 75,680,000 | 76,653,000 | 76,884,000 | 78,912,000 | 75,460,000 | 77,934,000 | 76,907,000 | 77,776,000 | 72,162,000 | 74,185,000 | 71,209,000 | 66,887,000 | 62,068,000 | 61,985,000 | 60,137,000 | 61,242,000 | 62,577,000 | 60,258,000 | 58,921,000 | 56,711,000 | 55,834,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 1,861,000 | 3,214,000 | 5,414,000 | 4,571,000 | 4,903,000 | 18,275,000 | 8,343,000 | 5,507,000 | 2,988,000 | 2,356,000 | 14,758,000 | 12,779,000 | 13,870,000 | 13,029,000 | 4,026,000 | 4,858,000 | 4,262,000 | 7,345,000 | 6,440,000 | 5,442,000 | 4,549,000 | 4,539,000 | 349,000 | 392,000 | 380,000 | 141,000 | 718,000 | 566,000 | 566,000 | 829,000 | 835,000 | 775,000 | 733,000 | 743,000 | 815,000 | 671,000 | 829,000 | 860,000 | 869,000 | 914,000 | 10,769,000 | 10,925,000 | 9,480,000 | 8,732,000 | 7,378,000 | 6,053,000 | 5,031,000 | 4,196,000 | 728,000 | 706,000 | 1,617,000 | 1,617,000 | 2,279,000 | 1,434,000 | 653,000 | 605,000 | 623,000 | 599,000 | 587,000 | 572,000 | 3,531,000 | 4,387,000 | 3,513,000 | 2,564,000 | 3,013,000 | 1,698,000 | 1,672,000 | 2,416,000 | 2,297,000 | 698,000 | 929,000 | 689,000 | 696,000 | 615,000 | 730,000 | 717,000 | 829,000 | 1,258,000 | 1,159,000 | |
total liabilities | 459,186,000 | 433,811,000 | 413,827,000 | 414,008,000 | 420,679,000 | 408,421,000 | 358,473,000 | 353,165,000 | 345,290,000 | 345,000,000 | 341,981,000 | 344,069,000 | 384,368,000 | 373,586,000 | 332,949,000 | 336,111,000 | 303,639,000 | 296,983,000 | 201,264,000 | 194,810,000 | 182,225,000 | 184,391,000 | 169,765,000 | 191,602,000 | 260,451,000 | 181,394,000 | 188,065,000 | 192,897,000 | 164,718,000 | 92,348,000 | 112,965,000 | 110,768,000 | 101,052,000 | 110,340,000 | 198,971,000 | 209,419,000 | 194,957,000 | 162,543,000 | 82,829,000 | 90,547,000 | 94,396,000 | 81,001,000 | 75,721,000 | 73,849,000 | 69,961,000 | 77,174,000 | 75,395,000 | 71,348,000 | 69,014,000 | 32,948,000 | 35,201,000 | 37,197,000 | 37,197,000 | 37,055,000 | 33,549,000 | 38,066,000 | 38,601,000 | 41,672,000 | 41,974,000 | 32,255,000 | 33,416,000 | 24,478,000 | 20,440,000 | 20,678,000 | 29,435,000 | 19,204,000 | 22,251,000 | 27,104,000 | 31,244,000 | 30,425,000 | 25,798,000 | 29,956,000 | 23,540,000 | 21,197,000 | 26,471,000 | 10,175,000 | 13,239,000 | 12,069,000 | 11,349,000 | 10,020,000 |
redeemable non-controlling interest - temporary equity | 313,437,000 | 293,311,000 | 277,661,000 | 263,298,000 | 260,047,000 | 269,025,000 | 186,602,000 | 184,354,000 | 190,733,000 | 174,828,000 | 174,697,000 | 165,514,000 | 164,283,000 | 167,515,000 | 148,155,000 | 151,400,000 | 158,008,000 | 155,262,000 | 138,217,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. physical therapy, inc. (“usph”) shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.01 par value... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock, 0.01 par value... | 175,000 | 174,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 172,000 | 152,000 | 152,000 | 152,000 | 152,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | 151,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital | 288,140,000 | 285,522,000 | 296,806,000 | 294,636,000 | 292,773,000 | 290,321,000 | 287,002,000 | 285,462,000 | 283,546,000 | 281,096,000 | 279,124,000 | 277,493,000 | 112,123,000 | 110,317,000 | 108,515,000 | 106,801,000 | 105,205,000 | 102,688,000 | 101,922,000 | 99,039,000 | 97,286,000 | 95,622,000 | 93,195,000 | 91,258,000 | 89,756,000 | 87,383,000 | 85,828,000 | 84,125,000 | 82,295,000 | 80,028,000 | 78,542,000 | 77,099,000 | 75,543,000 | 73,940,000 | 72,262,000 | 71,197,000 | 70,132,000 | 68,687,000 | 49,506,000 | 48,236,000 | 46,563,000 | 45,536,000 | 45,829,000 | 45,080,000 | 43,577,000 | 42,457,000 | 41,306,000 | 40,435,000 | 40,569,000 | 39,225,000 | 38,571,000 | 37,871,000 | 37,871,000 | 37,489,000 | 37,769,000 | 37,209,000 | 36,563,000 | 36,133,000 | 37,039,000 | 37,513,000 | 39,529,000 | 45,570,000 | 44,114,000 | 43,742,000 | 43,514,000 | 43,210,000 | 39,380,000 | 38,865,000 | 41,418,000 | 43,648,000 | 43,231,000 | 42,383,000 | 41,931,000 | 41,452,000 | 40,979,000 | 37,365,000 | 36,797,000 | 36,304,000 | 35,058,000 | 35,037,000 |
accumulated other comprehensive gain | 978,000 | 714,000 | 945,000 | 1,214,000 | 1,783,000 | 2,799,000 | 1,339,000 | 4,084,000 | 4,108,000 | 2,782,000 | 5,746,000 | 4,796,000 | 2,651,000 | 4,004,000 | 4,424,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
retained earnings | 216,876,000 | 227,216,000 | 237,272,000 | 236,356,000 | 234,161,000 | 227,265,000 | 225,873,000 | 226,482,000 | 223,573,000 | 223,772,000 | 238,557,000 | 237,665,000 | 234,760,000 | 232,948,000 | 235,683,000 | 232,247,000 | 227,243,000 | 224,395,000 | 219,338,000 | 216,286,000 | 210,375,000 | 212,015,000 | 203,201,000 | 195,473,000 | 182,785,000 | 184,352,000 | 181,135,000 | 176,610,000 | 168,952,000 | 167,396,000 | 164,821,000 | 165,991,000 | 162,907,000 | 162,406,000 | 157,702,000 | 155,068,000 | 152,642,000 | 150,342,000 | 160,746,000 | 157,161,000 | 152,219,000 | 144,888,000 | 140,933,000 | 136,491,000 | 134,186,000 | 130,683,000 | 126,934,000 | 121,970,000 | 119,206,000 | 116,555,000 | 117,538,000 | 113,835,000 | 113,835,000 | 111,321,000 | 113,112,000 | 109,615,000 | 105,825,000 | 102,405,000 | 97,509,000 | 96,632,000 | 92,679,000 | 89,876,000 | 85,729,000 | 83,255,000 | 78,804,000 | 75,632,000 | 78,923,000 | 75,822,000 | 72,200,000 | 69,446,000 | 67,213,000 | 64,682,000 | 61,827,000 | 59,442,000 | 56,956,000 | 54,836,000 | 52,533,000 | 50,704,000 | 45,892,000 | 44,408,000 |
treasury stock | -37,194,000 | -37,194,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -31,628,000 | -26,106,000 | |
total usph shareholders’ equity | 468,975,000 | 476,432,000 | 503,567,000 | 500,750,000 | 497,261,000 | 488,929,000 | 482,758,000 | 484,572,000 | 479,771,000 | 476,194,000 | 491,971,000 | 488,498,000 | 318,058,000 | 315,793,000 | 317,146,000 | 307,177,000 | 300,971,000 | 295,606,000 | 289,783,000 | 283,848,000 | 276,184,000 | 276,160,000 | 264,919,000 | 255,254,000 | 241,064,000 | 240,257,000 | 235,485,000 | 229,256,000 | 219,768,000 | 215,945,000 | 211,884,000 | 211,611,000 | 206,971,000 | 204,866,000 | 198,483,000 | 194,784,000 | 191,293,000 | 187,548,000 | ||||||||||||||||||||||||||||||||||||||||||
non-controlling interest - permanent equity | 459,000 | 456,000 | 1,215,000 | 1,544,000 | 1,700,000 | 1,092,000 | 1,358,000 | 1,043,000 | 1,462,000 | 1,216,000 | 1,537,000 | 1,500,000 | 1,418,000 | 1,260,000 | 1,458,000 | 1,756,000 | 1,245,000 | 1,575,000 | 834,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders’ equity and non-controlling interest - permanent equity | 469,434,000 | 476,888,000 | 504,782,000 | 502,294,000 | 498,961,000 | 490,021,000 | 484,116,000 | 485,615,000 | 481,233,000 | 477,410,000 | 493,508,000 | 489,998,000 | 319,476,000 | 317,053,000 | 318,604,000 | 308,933,000 | 302,216,000 | 290,617,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interest, usph shareholders’ equity and non-controlling interest - permanent equity | 1,242,057,000 | 1,204,010,000 | 1,196,270,000 | 1,179,600,000 | 1,179,687,000 | 1,167,467,000 | 1,029,191,000 | 1,023,134,000 | 1,017,256,000 | 997,238,000 | 1,010,186,000 | 999,581,000 | 868,127,000 | 858,154,000 | 799,708,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 3,775 and 3,506, respectively | 64,249,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 4,263 and 3,506, respectively | 67,629,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 3,928 and 3,506, respectively | 65,956,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 3,620 and 3,506, respectively | 64,760,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 3,506 and 2,736, respectively | 59,040,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 3,443 and 2,736, respectively | 57,022,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 3,184 and 2,736, respectively | 54,659,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 2,936 and 2,736, respectively | 55,363,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less provision for credit losses of 2,736 and 2,829, respectively | 51,866,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable - due to seller of acquired business | 3,204,000 | 3,203,000 | 3,203,000 | 3,203,000 | 3,203,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,487 and 2,829, respectively | 52,958,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,800 and 2,829, respectively | 54,285,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revolving line of credit | 38,000,000 | 31,000,000 | 118,000,000 | 114,000,000 | 33,000,000 | 38,000,000 | 16,000,000 | 16,000,000 | 7,000,000 | 33,000,000 | 114,000,000 | 46,000,000 | 51,000,000 | 62,000,000 | 29,000,000 | 38,000,000 | 54,000,000 | 56,000,000 | 42,000,000 | 54,000,000 | 56,000,000 | 69,000,000 | 58,000,000 | 46,000,000 | 36,000,000 | 42,500,000 | 52,500,000 | 46,000,000 | 41,000,000 | 41,500,000 | 34,500,000 | 46,500,000 | 45,000,000 | 45,500,000 | 40,000,000 | 14,150,000 | 15,750,000 | 20,400,000 | 20,400,000 | 17,400,000 | 16,100,000 | 20,000,000 | 24,200,000 | 23,500,000 | 26,400,000 | 15,800,000 | 4,800,000 | 5,500,000 | 3,600,000 | 10,900,000 | 400,000 | 3,400,000 | 10,600,000 | 12,600,000 | 11,400,000 | 8,800,000 | 14,800,000 | 9,800,000 | 7,000,000 | 12,000,000 | ||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,674 and 2,829, respectively | 56,647,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,829 and 2,768, respectively | 51,934,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,964 and 2,768, respectively | 49,747,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,948 and 2,768, respectively | 50,549,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss | -395,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interest, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
usph shareholders’ equity and non-controlling interest - permanent equity | 796,444,000 | 763,863,000 | 630,098,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,799 and 2,768, respectively | 49,335,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of notes payable | 799,000 | 830,000 | 672,000 | 1,017,000 | 5,079,000 | 4,899,000 | 4,999,000 | 4,635,000 | 728,000 | 728,000 | 718,000 | 690,000 | 1,066,000 | 1,434,000 | 4,769,000 | 4,817,000 | 5,317,000 | 4,044,000 | 2,745,000 | 2,345,000 | 1,219,000 | 1,227,000 | 986,000 | 1,044,000 | 1,253,000 | 1,412,000 | 800,000 | 932,000 | 883,000 | 850,000 | 850,000 | 775,000 | 825,000 | 575,000 | 800,000 | 659,000 | 659,000 | 459,000 | 609,000 | 609,000 | 483,000 | 433,000 | 533,000 | 434,000 | 250,000 | 250,000 | 379,000 | 637,000 | 1,113,000 | 1,013,000 | 1,086,000 | 1,234,000 | 1,307,000 | 1,380,000 | 1,153,000 | 1,179,000 | 771,000 | 812,000 | 854,000 | 537,000 | 537,000 | 562,000 | ||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,768 and 2,008, respectively | 46,272,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders' equity and non-controlling interest - permanent equity | 297,181,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interest, usph shareholders' equity and non-controlling interest - permanent equity | 749,426,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,728 and 2,008, respectively | 46,456,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,435 and 2,008, respectively | 45,144,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interests, usph shareholders’ equityand non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interests - temporary equity | 143,337,000 | 138,924,000 | 132,340,000 | 139,801,000 | 136,728,000 | 140,498,000 | 137,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests - permanent equity | 963,000 | 1,057,000 | 1,470,000 | 953,000 | 1,444,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders’ equity and non-controlling interests - permanent equity | 284,811,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
usph shareholders’ equity and non-controlling interests - permanent equity | 622,958,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,120 and 2,008, respectively | 45,394,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interests, usph shareholders’ equity and non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable - purchase of non-controlling interest | 4,828,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders' equity and non-controlling interests - permanent equity | 277,241,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, usph shareholders' equity and non-controlling interests - permanent equity | 598,390,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for credit losses of 2,008 and 2,698, respectively | 41,906,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, redeemable non-controlling interests, usphshareholders’ equity and non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders' equity and non-controlling interests | 277,630,000 | 241,701,000 | 221,173,000 | 213,098,000 | 212,748,000 | 208,485,000 | 199,937,000 | 195,966,000 | 192,714,000 | 188,688,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, usph shareholders' equity and non-controlling interests | 594,361,000 | 560,845,000 | 523,087,000 | 454,969,000 | 440,543,000 | 417,622,000 | 410,987,000 | 417,325,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,154 and 2,698, respectively | 39,439,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total usph shareholders’ equity and non-controlling interests | 265,872,000 | 256,688,000 | 242,304,000 | 237,327,000 | 230,747,000 | 216,875,000 | 206,070,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, redeemable non-controlling interests, usph shareholders’ equity and non-controlling interests | 575,438,000 | 585,018,000 | 643,253,000 | 565,193,000 | 557,010,000 | 443,166,000 | 418,982,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,470 and 2,698, respectively | 36,029,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests- permanent equity | 1,434,000 | 1,240,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,557 and 2,698, respectively | 42,649,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,698 and 2,672, respectively | 46,228,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred rent | 2,159,000 | 1,864,000 | 1,913,000 | 2,005,000 | 2,116,000 | 1,875,000 | 1,789,000 | 1,809,000 | 1,575,000 | 1,313,000 | 1,285,000 | 1,391,000 | 1,192,000 | 1,040,000 | 984,000 | 991,000 | 1,014,000 | 1,095,000 | 1,022,000 | 996,000 | 1,015,000 | 972,000 | 950,000 | 950,000 | 894,000 | 894,000 | 930,000 | 946,000 | 941,000 | 849,000 | 849,000 | 884,000 | 966,000 | 900,000 | 877,000 | 1,011,000 | 1,027,000 | 1,097,000 | 1,161,000 | 1,077,000 | 1,103,000 | 887,000 | 992,000 | 1,008,000 | 1,104,000 | 1,171,000 | 1,256,000 | 1,239,000 | 1,273,000 | 1,248,000 | 1,263,000 | |||||||||||||||||||||||||||||
preferred stock, .01 par value... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock, .01 par value... | 150,000 | 150,000 | 149,000 | 149,000 | 149,000 | 149,000 | 149,000 | 149,000 | 148,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 147,000 | 146,000 | 146,000 | 145,000 | 145,000 | 145,000 | 145,000 | 144,000 | 143,000 | 143,000 | 143,000 | 142,000 | 142,000 | 141,000 | 141,000 | 140,000 | 140,000 | 139,000 | 141,000 | 141,000 | 140,000 | 139,000 | 139,000 | 138,000 | 138,000 | 138,000 | 138,000 | 137,000 | 139,000 | 142,000 | 142,000 | 141,000 | 141,000 | 141,000 | 140,000 | 138,000 | 138,000 | 137,000 | 136,000 | ||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,569 and 2,672, respectively | 47,118,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redeemable non-controlling interests | 139,801,000 | 133,366,000 | 137,196,000 | 133,943,000 | 128,906,000 | 117,027,000 | 108,085,000 | 102,572,000 | 12,079,000 | 11,940,000 | 8,334,000 | 8,641,000 | 7,591,000 | 9,024,000 | 10,585,000 | 7,373,000 | 7,376,000 | 7,524,000 | 1,086,000 | 2,967,000 | 4,104,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-controlling interests | 1,842,000 | 1,491,000 | 1,405,000 | 930,000 | 1,214,000 | 1,137,000 | 1,514,000 | 1,204,000 | 1,454,000 | 1,182,000 | 1,421,000 | 1,140,000 | 39,967,000 | 40,494,000 | 42,146,000 | 27,178,000 | 26,734,000 | 26,113,000 | 20,934,000 | 21,382,000 | 27,542,000 | 23,398,000 | 22,414,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,666 and 2,672, respectively | 44,923,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable, net - sale and purchase of partnership interests | 9,401,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,692 and 2,672, respectively | 48,443,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. physical therapy, inc. ("usph") shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,672 and 2,273, respectively | 44,751,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
mandatorily redeemable non-controlling interests | 327,000 | 84,311,000 | 83,643,000 | 80,154,000 | 69,190,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,690 and 2,273, respectively | 43,899,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,790 and 2,273, respectively | 45,424,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,517 and 2,273, respectively | 46,228,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,273 and 1,792, respectively | 44,707,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,088 and 1,792, respectively | 43,561,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,859 and 1,792, respectively | 46,770,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,853 and 1,792, respectively | 43,244,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities, usph shareholders’ equity and non-controlling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable | 4,802,000 | 4,596,000 | 4,546,000 | 4,547,000 | 4,621,000 | 1,679,000 | 1,059,000 | 483,000 | 234,000 | 450,000 | 450,000 | 450,000 | 650,000 | 400,000 | 400,000 | 325,000 | 325,000 | 175,000 | 175,000 | 275,000 | 334,000 | 284,000 | 434,000 | 334,000 | 150,000 | 250,000 | 100,000 | 100,000 | 100,000 | 280,000 | 537,000 | 1,012,000 | 1,012,000 | 806,000 | 1,214,000 | 886,000 | 959,000 | 1,084,000 | 516,000 | 656,000 | 797,000 | 244,000 | 244,000 | |||||||||||||||||||||||||||||||||||||
total liabilities, usph shareholders' equity and non-controlling interests | 387,671,000 | 351,231,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,792 and 1,444, respectively | 38,840,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of -0- and 198, respectively | 2,649,000 | 2,272,000 | 2,335,000 | 2,345,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,770 and 1,444, respectively | 38,522,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. physical therapy, inc. shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total u. s. physical therapy, inc. shareholders’ equity | 178,771,000 | 173,916,000 | 167,301,000 | 146,280,000 | 128,290,000 | 124,295,000 | 124,624,000 | 120,220,000 | 120,220,000 | 117,323,000 | 119,394,000 | 115,336,000 | 110,900,000 | 107,049,000 | 103,061,000 | 102,658,000 | 100,720,000 | 103,957,000 | 98,354,000 | 95,507,000 | 90,828,000 | 87,352,000 | 86,813,000 | 83,196,000 | 82,129,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
total equity | 218,738,000 | 214,410,000 | 209,447,000 | 186,120,000 | 182,014,000 | 176,201,000 | 167,214,000 | 163,039,000 | 164,299,000 | 154,319,000 | 151,017,000 | 146,709,000 | 147,229,000 | 139,680,000 | 139,680,000 | 134,659,000 | 136,391,000 | 132,566,000 | 125,835,000 | 121,580,000 | 122,065,000 | 114,582,000 | 112,958,000 | 116,383,000 | 106,514,000 | 103,788,000 | 99,189,000 | 92,225,000 | 91,861,000 | 88,561,000 | 87,789,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and equity | 309,901,000 | 313,598,000 | 311,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,672 and 1,444, respectively | 39,356,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,568 and 1,444, respectively | 38,217,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u. s. physical therapy, inc. shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,556 and 1,669, respectively | 35,106,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 198 and 198, respectively | 1,939,000 | 1,338,000 | 1,378,000 | 1,503,000 | 1,906,000 | 1,924,000 | 1,698,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
fixed assets: - sum | 69,163,000 | 67,602,000 | 66,107,000 | 64,743,000 | 63,375,000 | 61,173,000 | 60,856,000 | 59,666,000 | 59,345,000 | 58,313,000 | 57,174,000 | 56,451,000 | 55,637,000 | 55,478,000 | 55,488,000 | 55,014,000 | 53,686,000 | 53,530,000 | 53,153,000 | 51,731,000 | 51,219,000 | 51,070,000 | 50,985,000 | 51,416,000 | 50,702,000 | 50,325,000 | 49,008,000 | 48,213,000 | 47,441,000 | 46,349,000 | 46,134,000 | 45,449,000 | 40,821,000 | 39,652,000 | 38,944,000 | 38,719,000 | 37,566,000 | |||||||||||||||||||||||||||||||||||||||||||
other intangible assets | 23,798,000 | 24,167,000 | 24,537,000 | 24,907,000 | 22,615,000 | 15,727,000 | 15,916,000 | 14,479,000 | 14,672,000 | 14,029,000 | 14,230,000 | 14,230,000 | 12,146,000 | 12,326,000 | 12,522,000 | 9,515,000 | 9,603,000 | 9,773,000 | 9,948,000 | 7,166,000 | 7,308,000 | 7,448,000 | 7,569,000 | 5,830,000 | 5,955,000 | 6,079,000 | 6,203,000 | 6,327,000 | 6,452,000 | 5,370,000 | 3,926,000 | 3,981,000 | 3,930,000 | |||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders' equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u. s. physical therapy, inc. shareholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total u. s. physical therapy, inc. shareholders' equity | 158,942,000 | 155,280,000 | 150,088,000 | 141,657,000 | 136,757,000 | 130,921,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,618 and 1,669, respectively | 34,830,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,633 and 1,669, respectively | 34,673,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,669 and 1,430, respectively | 32,891,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders' equity | 244,551,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,811 and 1,430, respectively | 33,809,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,713 and 1,430, respectively | 34,286,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,583 and 1,430, respectively | 32,755,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,430 and 1,595, respectively | 30,820,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 198 and 514, respectively | 1,844,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncontrolling interests | 22,727,000 | 22,605,000 | 19,460,000 | 19,460,000 | 17,336,000 | 16,997,000 | 17,230,000 | 14,935,000 | 14,531,000 | 19,004,000 | 11,924,000 | 12,238,000 | 12,426,000 | 8,160,000 | 8,281,000 | 8,361,000 | 4,873,000 | 5,048,000 | 5,365,000 | 5,660,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,427 and 1,595, respectively | 27,289,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable—other, less allowance for doubtful accounts of 198 and 514, respectively | 1,263,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable—trade | 1,301,000 | 1,732,000 | 1,377,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,469 and 1,595, respectively | 27,564,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 412 and 514, respectively | 1,700,000 | 1,607,000 | 1,607,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,521 and 1,595, respectively | 28,969,000 | 28,969,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,595 and 2,154, respectively | 25,973,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable—other, less allowance for doubtful accounts of 514 and 883, respectively | 1,703,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash | 10,683,000 | 8,811,000 | 10,440,000 | 9,475,000 | 8,992,000 | 10,666,000 | 9,720,000 | 7,176,000 | 11,471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,687 and 2,154, respectively | 26,784,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 373 and 883, respectively | 1,640,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable — trade | 1,665,000 | 1,809,000 | 1,810,000 | 1,517,000 | 1,477,000 | 1,237,000 | 1,224,000 | 1,522,000 | 1,188,000 | 1,292,000 | 1,211,000 | 1,090,000 | 1,280,000 | 1,481,000 | 1,275,000 | 1,514,000 | 1,321,000 | 1,555,000 | 1,212,000 | 696,000 | 1,059,000 | 1,601,000 | 1,721,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,930 and 2,154, respectively | 28,768,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other, less allowance for doubtful accounts of 408 and 883, respectively | 1,737,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,892 and 2,154, respectively | 29,456,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable—other, less allowance for doubtful accounts of 186 and 883, respectively | 1,979,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,154 and 2,190, respectively | 28,333,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 883 and 83, respectively | 1,614,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,155 and 2,190, respectively | 28,130,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful. accounts of 916 and 83, respectively | 1,999,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,570 and 2,190, respectively | 27,468,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 136 and 83, respectively | 2,613,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,500 and 2,190, respectively | 27,987,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 106 and 83, respectively | 1,941,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,190 and 1,830, respectively | 24,814,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 83 and 42, respectively | 1,555,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,226 and 1,830, respectively | 23,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 81 and 42, respectively | 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,215 and 1,830, respectively | 23,115,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 59 and 42, respectively | 1,565,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,031 and 1,830, respectively | 23,482,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 50 and 42, respectively | 2,146,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,830 and 2,275, respectively | 22,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other, less allowance for doubtful accounts of 42 and — , respectively | 1,331,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u. s. physical therapy, inc. shareholders’s equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,976 and 2,275, respectively | 23,715,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable — other | 706,000 | 707,000 | 701,000 | 898,000 | 920,000 | 1,020,000 | 1,150,000 | 1,075,000 | 793,000 | 602,000 | 775,000 | 761,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,062 and 2,275, respectively | 23,696,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,177 and 2,275, respectively | 25,650,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,275 and 2,184, respectively | 25,853,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interests in subsidiary limited partnerships | 6,214,000 | 6,135,000 | 6,347,000 | 5,847,000 | 5,648,000 | 5,484,000 | 3,994,000 | 3,723,000 | 3,871,000 | 3,344,000 | 3,024,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 81,608,000 | 78,958,000 | 75,578,000 | 72,271,000 | 69,407,000 | 66,447,000 | 60,711,000 | 57,840,000 | 55,517,000 | 53,475,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,128 and 2,184, respectively | 26,935,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable – other | 872,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,181 and 2,184, respectively | 28,434,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,142 and 2,184, respectively | 27,581,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
marketable securities — available for sale | 1,900,000 | 1,460,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 2,184 and 1,567, respectively | 25,574,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,950 and 1,567, respectively | 25,976,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,745 and 1,567, respectively | 22,328,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,669 and 1,567, respectively | 21,873,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,567 and 1,621, respectively | 21,503,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts of 1,656 and 1,621, respectively | 20,372,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable -- other | 839,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable -- trade | 1,410,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable - long-term portion | 415,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
13,647,047 and 13,645,167 shares issued at march 31, 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
and december 31, 2005, respectively | 136,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital, equity-based compensation | 222,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
march 31, 2006 and december 31, 2005, respectively | -26,966,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders' equity | 54,342,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable, less allowance for doubtful accounts of 1,621 and 2,447, respectively | 19,661,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable — long-term portion | 483,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2013-03-13 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income including non-controlling interest | 9,175,000 | 17,642,000 | 17,720,000 | 13,468,000 | 12,494,000 | 9,777,000 | 11,712,000 | 11,617,000 | -1,293,000 | 12,222,000 | 14,864,000 | 11,427,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income including non-controlling interest to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 4,635,000 | 5,832,000 | 6,057,000 | 5,867,000 | 5,685,000 | 4,387,000 | 4,514,000 | 4,095,000 | 4,113,000 | 3,967,000 | 3,827,000 | 3,788,000 | 3,793,000 | 3,652,000 | 3,474,000 | 3,824,000 | 3,072,000 | 3,035,000 | 2,803,000 | 2,681,000 | 2,467,000 | 2,733,000 | 2,726,000 | 2,607,000 | 2,718,000 | 2,419,000 | 2,558,000 | 2,400,000 | 2,420,000 | 2,469,000 | 2,398,000 | 2,468,000 | 2,441,000 | 2,480,000 | 2,433,000 | 2,356,000 | 2,569,000 | 2,052,000 | 2,067,000 | 2,091,000 | 1,982,000 | 1,867,000 | 1,807,000 | 2,058,000 | 1,857,000 | 1,438,000 | 1,387,000 | 1,381,000 | 1,451,000 | 1,378,000 | 1,352,000 | 1,352,000 | 1,271,000 | 1,370,000 | 1,312,000 | 1,334,000 | 1,341,000 | 1,356,000 | 1,422,000 | 1,330,000 | 1,391,000 | 1,411,000 | 1,434,000 | 1,431,000 | 1,458,000 | 1,492,000 | 1,475,000 | 1,472,000 | 1,520,000 | 1,542,000 | 1,420,000 | 1,484,000 | 1,456,000 | 1,247,000 | 1,158,000 | 1,125,000 | 1,090,000 |
provision for credit losses | 1,731,000 | 2,073,000 | 1,995,000 | 1,848,000 | 1,847,000 | 1,721,000 | 1,717,000 | 1,627,000 | 1,572,000 | 1,525,000 | 1,563,000 | 1,512,000 | 1,356,000 | 1,336,000 | 1,551,000 | 1,305,000 | 1,383,000 | 1,358,000 | 1,364,000 | 1,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity-based awards compensation expense | 2,119,000 | 2,263,000 | 2,117,000 | 1,771,000 | 1,986,000 | 1,921,000 | 1,919,000 | 1,997,000 | 1,785,000 | 1,859,000 | 1,786,000 | 1,806,000 | 1,802,000 | 1,802,000 | 1,814,000 | 1,846,000 | 1,587,000 | 2,875,000 | 1,754,000 | 1,651,000 | 2,592,000 | 1,936,000 | 1,503,000 | 1,886,000 | 1,723,000 | 1,704,000 | 1,830,000 | 1,728,000 | 1,486,000 | 1,516,000 | 1,556,000 | 1,381,000 | 1,622,000 | 1,065,000 | 1,065,000 | 1,280,000 | 1,214,000 | 1,264,000 | 1,263,000 | 1,221,000 | 1,162,000 | 1,216,000 | 990,000 | 907,000 | 863,000 | 858,000 | 735,000 | 651,000 | 722,000 | 731,000 | 639,000 | 639,000 | 513,000 | 546,000 | 496,000 | 547,000 | 541,000 | 528,000 | 519,000 | 444,000 | 373,000 | 341,000 | 272,000 | 306,000 | 360,000 | 415,000 | 384,000 | 414,000 | 417,000 | 397,000 | 421,000 | 339,000 | 341,000 | 356,000 | 323,000 | 257,000 | 222,000 |
amortization of debt issue costs | 107,000 | 105,000 | 104,000 | 106,000 | 105,000 | 107,000 | 104,000 | 106,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in deferred income taxes | 243,000 | 3,884,000 | 2,037,000 | 5,242,000 | 4,760,000 | -165,000 | -1,173,000 | 1,943,000 | -903,000 | 3,594,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in revaluation of put-right liability | -84,000 | 663,000 | 339,000 | 404,000 | -54,000 | -167,000 | 223,000 | 80,000 | -2,926,000 | 145,000 | 50,000 | 149,000 | 776,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of contingent earn-out consideration | 5,240,000 | -5,872,000 | -5,113,000 | 1,898,000 | 4,046,000 | -612,000 | 1,747,000 | 698,000 | -520,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity of earnings in unconsolidated affiliate | -322,000 | -361,000 | -401,000 | -393,000 | -264,000 | -231,000 | -248,000 | -271,000 | -149,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of clinics and fixed assets | 0 | -29,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of partnership | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of goodwill and other intangible assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of assets held for sale | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable | 1,649,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable - other | -664,000 | 3,204,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other current and long term assets | -2,263,000 | -3,729,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable and accrued expenses | 3,110,000 | -2,994,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 293,000 | 620,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities | 24,932,000 | 19,940,000 | 34,861,000 | -4,675,000 | 19,409,000 | 22,120,000 | 28,992,000 | 4,419,000 | 26,835,000 | 16,364,000 | 27,430,000 | 11,349,000 | 17,299,000 | 13,727,000 | 15,862,000 | 11,649,000 | 15,905,000 | 24,945,000 | 17,882,000 | 17,674,000 | 25,393,000 | 26,246,000 | 31,976,000 | 16,380,000 | 15,984,000 | 17,843,000 | 15,058,000 | 13,563,000 | 19,000,000 | 23,384,000 | 15,090,000 | 15,531,000 | 15,695,000 | 18,640,000 | 8,020,000 | 14,171,000 | 9,022,000 | 8,664,000 | 18,653,000 | 14,711,000 | 9,620,000 | 16,220,000 | 3,019,000 | 16,368,000 | 7,772,000 | 17,364,000 | 3,690,000 | 15,936,000 | 8,143,000 | 15,863,000 | 4,853,000 | 4,853,000 | 9,899,000 | 10,383,000 | 13,796,000 | 5,171,000 | 12,062,000 | 7,752,000 | 7,146,000 | 5,695,000 | 6,739,000 | 11,242,000 | 6,511,000 | 6,029,000 | 6,427,000 | 9,826,000 | 8,258,000 | 6,433,000 | 9,400,000 | 10,813,000 | 6,059,000 | 3,900,000 | 6,617,000 | 5,308,000 | 1,722,000 | 5,400,000 | 4,981,000 |
capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
free cash flows | 24,932,000 | 19,940,000 | 34,861,000 | -4,675,000 | 19,409,000 | 22,120,000 | 28,992,000 | 4,419,000 | 26,835,000 | 16,364,000 | 27,430,000 | 11,349,000 | 17,299,000 | 13,727,000 | 15,862,000 | 11,649,000 | 15,905,000 | 24,945,000 | 17,882,000 | 17,674,000 | 25,393,000 | 26,246,000 | 31,976,000 | 16,380,000 | 15,984,000 | 17,843,000 | 15,058,000 | 13,563,000 | 19,000,000 | 23,384,000 | 15,090,000 | 15,531,000 | 15,695,000 | 18,640,000 | 8,020,000 | 14,171,000 | 9,022,000 | 8,664,000 | 18,653,000 | 14,711,000 | 9,620,000 | 16,220,000 | 3,019,000 | 16,368,000 | 7,772,000 | 17,364,000 | 3,690,000 | 15,936,000 | 8,143,000 | 15,863,000 | 4,853,000 | 4,853,000 | 9,899,000 | 10,383,000 | 13,796,000 | 5,171,000 | 12,062,000 | 7,752,000 | 7,146,000 | 5,695,000 | 6,739,000 | 11,242,000 | 6,511,000 | 6,029,000 | 6,427,000 | 9,826,000 | 8,258,000 | 6,433,000 | 9,400,000 | 10,813,000 | 6,059,000 | 3,900,000 | 6,617,000 | 5,308,000 | 1,722,000 | 5,400,000 | 4,981,000 |
investing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of fixed assets | -3,926,000 | -4,315,000 | -3,251,000 | -2,579,000 | -2,489,000 | -2,523,000 | -2,336,000 | -1,838,000 | -2,220,000 | -2,551,000 | -2,464,000 | -2,059,000 | -958,000 | -2,721,000 | -2,041,000 | -2,528,000 | -2,205,000 | -2,695,000 | -1,693,000 | -1,608,000 | -2,145,000 | -866,000 | -1,874,000 | -2,754,000 | -2,761,000 | -2,552,000 | -2,379,000 | -2,497,000 | -1,886,000 | -2,037,000 | -1,866,000 | -1,404,000 | -1,519,000 | -2,331,000 | -1,658,000 | -1,587,000 | -2,640,000 | -2,167,000 | -1,715,000 | -1,738,000 | -1,817,000 | -1,454,000 | -1,419,000 | -1,255,000 | -1,780,000 | -1,283,000 | -849,000 | -1,179,000 | -1,064,000 | -1,124,000 | -1,270,000 | -1,270,000 | -1,286,000 | -1,005,000 | -1,047,000 | -896,000 | -794,000 | -944,000 | -624,000 | -860,000 | -1,003,000 | -1,082,000 | -1,000,000 | -588,000 | -594,000 | -992,000 | -728,000 | -1,562,000 | -1,126,000 | -1,076,000 | -1,169,000 | -928,000 | -1,187,000 | -745,000 | -1,318,000 | -784,000 | -1,480,000 |
purchase of majority interest in businesses, net of cash acquired | -2,679,000 | -4,211,000 | -91,891,000 | -2,501,000 | -22,724,000 | -15,971,000 | -3,588,000 | -14,954,000 | -2,244,000 | -5,796,000 | -41,215,000 | -6,774,000 | -557,000 | -11,242,000 | -64,234,000 | -2,187,000 | -8,655,000 | -11,747,000 | -8,585,000 | -3,689,000 | 0 | -11,633,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of redeemable non-controlling interest, temporary equity | -1,338,000 | -152,000 | -7,520,000 | -907,000 | -1,095,000 | -727,000 | -3,528,000 | -2,702,000 | -3,182,000 | 0 | -2,626,000 | -5,178,000 | -891,000 | -5,448,000 | -6,437,000 | -2,211,000 | -13,549,000 | -5,380,000 | -17,298,000 | -699,000 | -536,000 | -1,852,000 | -2,952,000 | -3,646,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of non controlling interest, permanent equity | -77,000 | -47,000 | -248,000 | -229,000 | -29,000 | -498,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of non-controlling interest, permanent equity | 0 | 0 | 3,000 | 23,000 | 72,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of notes receivable related to sales of redeemable non-controlling interest | 144,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of partnership interest - redeemable non-controlling interest, temporary equity | 67,000 | 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions from unconsolidated affiliate | 322,000 | 425,000 | 354,000 | 310,000 | 242,000 | 306,000 | 165,000 | 367,000 | 149,000 | 179,000 | 257,000 | 245,000 | 39,000 | 672,000 | 416,000 | 132,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of partnership interest, clinics and fixed assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other | -167,000 | 303,000 | 184,000 | 44,000 | 778,000 | -328,000 | 156,000 | 88,000 | 271,000 | 125,000 | -95,000 | 0 | -81,000 | 93,000 | -121,000 | -20,000 | -5,000 | 12,000 | 278,000 | 129,000 | -24,000 | 99,000 | 9,000 | 12,000 | 209,000 | 6,000 | -104,000 | 56,000 | 581,000 | 0 | 0 | 557,000 | -557,000 | 1,000 | 0 | 45,000 | 132,000 | 44,000 | 1,000 | -310,000 | 0 | 33,000 | 33,000 | 1,208,000 | -180,000 | -217,000 | -374,000 | -13,000 | -138,000 | -24,000 | -54,000 | ||||||||||||||||||||||||||
net cash from investing activities | -5,444,000 | -11,935,000 | -12,706,000 | -6,628,000 | -94,853,000 | -5,842,000 | -28,291,000 | -20,464,000 | -8,414,000 | -16,941,000 | -6,979,000 | -12,681,000 | -43,391,000 | -14,338,000 | -7,596,000 | -15,944,000 | -79,878,000 | -10,883,000 | -20,172,000 | -13,203,000 | -28,288,000 | -4,836,000 | -2,156,000 | -15,923,000 | -6,028,000 | -6,724,000 | -20,611,000 | -4,630,000 | -2,029,000 | -9,248,000 | -10,221,000 | -2,411,000 | -4,326,000 | -2,401,000 | -19,653,000 | -17,195,000 | -12,156,000 | -2,581,000 | -1,636,000 | -16,119,000 | -3,619,000 | -10,021,000 | -8,215,000 | -1,773,000 | -3,318,000 | -13,998,000 | -3,791,000 | -37,643,000 | -1,365,000 | -7,014,000 | -6,427,000 | -6,427,000 | -2,737,000 | -1,546,000 | -7,276,000 | -2,545,000 | -2,099,000 | -12,142,000 | -16,493,000 | -872,000 | -10,461,000 | -1,386,000 | -521,000 | -9,265,000 | -3,962,000 | -1,106,000 | -706,000 | -1,552,000 | -8,858,000 | -1,903,000 | -10,083,000 | -4,032,000 | -1,786,000 | -18,127,000 | -1,756,000 | -1,867,000 | -2,334,000 |
financing activities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costs | 0 | -9,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from revolving facility | 43,000,000 | 73,000,000 | 56,500,000 | 17,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions to non-controlling interest, permanent and temporary equity | -4,659,000 | -3,913,000 | -7,044,000 | -3,653,000 | -3,312,000 | -3,081,000 | -5,158,000 | -3,160,000 | -4,323,000 | -3,346,000 | -5,134,000 | -3,297,000 | -3,588,000 | -4,558,000 | -3,491,000 | -3,711,000 | -2,601,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends paid to shareholders | -6,842,000 | -6,842,000 | -6,642,000 | -6,634,000 | -6,445,000 | -6,445,000 | -5,331,000 | -5,331,000 | -4,831,000 | -4,906,000 | 0 | 0 | -3,832,000 | -3,832,000 | -2,918,000 | -2,918,000 | -5,031,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments on revolving facility | -39,000,000 | -71,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments on term loan | -1,875,000 | -1,875,000 | -1,875,000 | -3,750,000 | 0 | -1,875,000 | -937,000 | -938,000 | -937,000 | -938,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash from the repurchase of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
principal payments on notes payable | -71,000 | -366,000 | -1,155,000 | -473,000 | -1,226,000 | -613,000 | -721,000 | -392,000 | -1,526,000 | -1,788,000 | -664,000 | -422,000 | -434,000 | -158,000 | -6,000 | -332,000 | -237,000 | -455,000 | -4,062,000 | -145,000 | -337,000 | -386,000 | -200,000 | -114,000 | -24,000 | -352,000 | -575,000 | -482,000 | -1,750,000 | -396,000 | -1,075,000 | -823,000 | -451,000 | 1,000 | -75,000 | -702,000 | -208,000 | -59,000 | -283,000 | -250,000 | |||||||||||||||||||||||||||||||||||||
net cash from financing activities | -15,020,000 | -10,989,000 | -27,252,000 | 9,124,000 | -153,000 | -12,230,000 | -20,080,000 | -4,490,000 | -13,281,000 | -12,476,000 | 107,682,000 | 2,343,000 | 19,772,000 | -10,047,000 | 16,077,000 | -43,000 | 73,352,000 | -15,293,000 | 4,772,000 | -19,452,000 | 5,684,000 | -34,836,000 | -75,816,000 | 65,546,000 | -14,264,000 | -18,122,000 | 20,174,000 | -12,063,000 | -25,844,000 | -6,854,000 | -19,063,000 | 6,721,000 | 8,131,000 | 8,157,000 | -11,512,000 | -15,770,000 | 4,836,000 | 1,585,000 | -7,784,000 | 5,482,000 | -16,148,000 | -1,564,000 | -7,193,000 | 3,964,000 | 22,482,000 | -4,942,000 | -8,846,000 | 187,000 | 187,000 | -6,174,000 | -6,965,000 | -8,149,000 | -2,169,000 | -9,455,000 | 4,873,000 | 7,673,000 | -3,336,000 | 3,181,000 | -7,312,000 | -10,285,000 | 8,278,000 | -5,362,000 | -9,833,000 | -8,194,000 | -3,913,000 | 418,000 | -7,830,000 | 2,900,000 | 1,353,000 | -6,421,000 | 10,417,000 | -1,091,000 | -1,392,000 | -1,788,000 | |||
net increase in cash and cash equivalents | -75,597,000 | 4,048,000 | -19,379,000 | -20,535,000 | 128,133,000 | 1,011,000 | 9,379,000 | -1,231,000 | 2,482,000 | -14,981,000 | 2,789,000 | -13,426,000 | -45,996,000 | 66,003,000 | -4,308,000 | -7,003,000 | -8,873,000 | 5,093,000 | 7,335,000 | -2,120,000 | 4,515,000 | -2,824,000 | -4,912,000 | 5,107,000 | 5,023,000 | -5,429,000 | 1,247,000 | 3,428,000 | 7,586,000 | -1,585,000 | 286,000 | -1,387,000 | -1,387,000 | -2,897,000 | -1,113,000 | -642,000 | 968,000 | 960,000 | 1,080,000 | -1,124,000 | 1,221,000 | -1,590,000 | -2,402,000 | -1,125,000 | 2,141,000 | 859,000 | |||||||||||||||||||||||||||||||
cash and cash equivalents - beginning of period | 0 | 0 | 0 | 41,362,000 | 0 | 0 | 0 | 152,825,000 | 0 | 0 | 0 | 31,594,000 | 0 | 0 | 0 | 28,567,000 | 0 | 0 | 0 | 32,918,000 | 0 | 0 | 0 | 23,548,000 | 0 | 0 | 0 | 23,368,000 | 0 | 0 | 0 | 21,933,000 | 0 | 0 | 0 | 20,047,000 | 0 | 0 | 0 | 15,778,000 | 0 | 0 | 14,271,000 | 11,671,000 | 11,671,000 | ||||||||||||||||||||||||||||||||
cash and cash equivalents - end of period | 4,468,000 | -2,984,000 | -5,097,000 | 39,183,000 | -75,597,000 | 4,048,000 | -19,379,000 | 132,290,000 | 5,140,000 | -13,053,000 | 128,133,000 | 32,605,000 | -6,320,000 | -10,658,000 | 24,343,000 | 24,229,000 | 9,379,000 | -1,231,000 | 2,482,000 | 17,937,000 | 2,789,000 | -13,426,000 | -45,996,000 | 89,551,000 | -4,308,000 | -7,003,000 | 14,621,000 | 20,238,000 | -8,873,000 | 5,093,000 | 7,335,000 | 19,813,000 | 4,515,000 | -2,824,000 | -4,912,000 | 25,154,000 | 5,023,000 | -5,429,000 | 1,247,000 | 19,206,000 | 10,284,000 | 10,284,000 | 15,861,000 | ||||||||||||||||||||||||||||||||||
supplemental disclosures of cash flow information | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the period for: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes | 2,539,000 | 1,976,000 | 2,474,000 | 7,359,000 | -927,000 | 827,000 | 4,565,000 | 367,000 | 2,195,000 | 1,490,000 | 799,000 | 442,000 | 86,000 | 3,005,000 | 4,443,000 | 81,000 | 1,437,000 | 3,810,000 | 6,905,000 | 62,000 | 3,256,000 | 4,364,000 | -185,000 | 242,000 | 398,000 | 5,119,000 | 4,026,000 | 313,000 | 226,000 | 1,474,000 | 4,542,000 | 2,941,000 | 484,000 | 543,000 | 7,430,000 | 86,000 | 533,000 | 4,538,000 | 3,248,000 | 2,265,000 | 1,824,000 | 2,560,000 | 1,275,000 | 1,333,000 | 4,685,000 | 2,993,000 | 242,000 | -291,000 | 2,403,000 | 1,822,000 | 177,000 | 177,000 | 1,161,000 | 1,314,000 | 3,310,000 | 576,000 | 1,156,000 | 4,514,000 | 2,752,000 | 615,000 | 1,636,000 | 1,381,000 | 4,368,000 | 419,000 | 1,499,000 | 1,874,000 | 3,328,000 | 1,744,000 | 128,000 | 808,000 | 1,946,000 | 1,518,000 | 1,405,000 | 1,391,000 | 2,576,000 | 109,000 | 256,000 |
interest paid | 2,126,000 | 2,622,000 | 2,478,000 | 2,205,000 | 1,579,000 | 1,922,000 | 1,864,000 | 1,844,000 | 1,663,000 | 2,981,000 | 2,634,000 | 1,377,000 | 3,528,000 | 840,000 | 794,000 | 525,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash investing and financing transactions during the period: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of businesses - seller financing portion | 0 | -45,000 | 1,500,000 | 0 | 360,000 | 750,000 | 450,000 | 74,000 | 300,000 | 1,250,000 | 1,250,000 | 250,000 | 300,000 | 325,000 | 496,000 | 0 | 300,000 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities assumed associated with a purchase of a business | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
fair market value of initial contingent consideration related to purchase of businesses | -439,000 | 2,672,000 | 1,800,000 | 1,259,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable related to purchase of redeemable non-controlling interest, temporary equity | 38,000 | 46,000 | 0 | 89,000 | 5,000 | 70,000 | 396,000 | 10,000 | 611,000 | 0 | 126,000 | 702,000 | 246,000 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payable related to the purchase of redeemable non-controlling interest, temporary equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
offset to notes receivable associated with purchase of redeemable non-controlling interest | 180,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes receivable related to sale of redeemable non-controlling interest | 646,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable related to the purchase of non-controlling interest, permanent equity | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payable related to the purchase of non-controlling interest, permanent equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes receivable related to the sale of non-controlling interest, permanent equity | 44,000 | 0 | 0 | 39,000 | 0 | 243,000 | 61,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of restricted stock related to purchase of business | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of fixed assets | -18,000 | 229,000 | 46,000 | 5,000 | 7,000 | -83,000 | 40,000 | 54,000 | 18,000 | 32,000 | 33,000 | 121,000 | -19,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of a partnership | 0 | 0 | 123,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of interest in businesses, net of cash acquired | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of non-controlling interest, permanent equity | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity | 134,000 | 0 | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of partnership | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease) in cash and cash equivalents | -2,984,000 | -5,097,000 | -2,179,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
offset of notes receivable associated with purchase of redeemable non-controlling interest | 0 | 552,000 | 0 | 75,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes receivable related to sale of redeemable non-controlling interest, temporary equity | 1,357,000 | 1,673,000 | 87,000 | 315,000 | 1,072,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
patient accounts receivable,net | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of notes receivable related to redeemable non-controlling interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable related to purchase of non-controlling interest, temporary equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on change in fair value of contingent earn-out consideration | -4,822,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in patient accounts receivable | -7,341,000 | 3,524,000 | -3,760,000 | 14,000 | -5,124,000 | -230,000 | -74,000 | 658,000 | -5,999,000 | -2,694,000 | -126,000 | -2,783,000 | -4,676,000 | 3,209,000 | 1,795,000 | -3,215,000 | -58,000 | -4,898,000 | -2,342,000 | 1,049,000 | 641,000 | -2,782,000 | -1,533,000 | 2,092,000 | -2,464,000 | -1,542,000 | -727,000 | -99,000 | -264,000 | -2,185,000 | -1,268,000 | -695,000 | -2,185,000 | -436,000 | -510,000 | -1,440,000 | -3,002,000 | -2,071,000 | -776,000 | 887,000 | -3,429,000 | -3,429,000 | -365,000 | 315,000 | 566,000 | -2,179,000 | -83,000 | 46,000 | -3,774,000 | -1,583,000 | -503,000 | -1,218,000 | |||||||||||||||||||||||||
decrease in accounts receivable - other | 774,000 | 4,244,000 | -1,689,000 | -717,000 | -2,145,000 | -800,000 | -867,000 | -91,000 | 220,000 | 931,000 | 447,000 | -1,330,000 | 291,000 | -3,697,000 | -516,000 | 63,000 | 10,000 | 43,000 | 40,000 | 125,000 | -226,000 | 146,000 | 74,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in other current and long term assets | -6,209,000 | -433,000 | -2,686,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in accounts payable and accrued expenses | -14,229,000 | -6,678,000 | 5,624,000 | -5,241,000 | -2,460,000 | -2,460,000 | -1,016,000 | -2,028,000 | -58,000 | -1,066,000 | -324,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in long term liabilities | -1,284,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of partnership | 700,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of redeemable non-controlling interest, temporary equity, recorded in accrued liabilities | 6,672,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dividends payable to usph shareholders | 6,836,000 | 6,630,000 | 5,617,000 | 5,327,000 | 4,514,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable - other | -5,588,000 | 1,391,000 | 1,634,000 | -3,985,000 | 1,275,000 | -1,546,000 | 711,000 | -796,000 | -1,752,000 | -1,493,000 | 1,462,000 | -1,973,000 | -495,000 | 2,867,000 | -1,020,000 | -2,085,000 | -849,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in other long-term liabilities | -1,359,000 | -2,480,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from term loan | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of deferred financing costs | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
others | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in other current and long term assets | -166,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts payable and accrued expenses | 6,484,000 | -3,187,000 | 1,445,000 | 128,000 | 8,201,000 | -7,641,000 | 3,969,000 | -1,068,000 | 9,017,000 | 2,451,000 | 2,027,000 | -3,769,000 | 4,340,000 | -5,054,000 | 274,000 | -4,866,000 | 4,897,000 | -2,544,000 | 7,389,000 | -1,147,000 | 3,083,000 | -272,000 | 5,315,000 | -2,184,000 | -2,537,000 | 3,393,000 | 4,322,000 | -3,728,000 | 2,684,000 | 685,000 | -956,000 | -939,000 | -647,000 | -240,000 | -225,000 | 1,526,000 | 1,313,000 | ||||||||||||||||||||||||||||||||||||||||
increase in other long-term liabilities | -1,137,000 | 496,000 | 52,000 | 292,000 | 2,979,000 | 2,459,000 | -5,603,000 | 209,000 | 2,345,000 | -1,743,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of redeemable non-controlling interest, temporary equity | 0 | 37,000 | 73,000 | 35,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of interest in businesses - seller financing portion | 6,440,000 | 455,000 | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
initial contingent consideration related to purchase of interest of businesses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable related to purchase of non-controlling interest, permanent equity | -280,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of partnership interest - redeemable non-controlling interest | 130,000 | 107,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of fixed assets | 423,000 | -295,000 | 316,000 | 0 | -1,000 | 6,000 | 59,000 | -1,000 | 1,000 | 14,000 | 5,000 | 0 | 62,000 | 19,000 | 0 | 0 | 42,000 | -1,000 | 4,000 | 21,000 | 22,000 | 10,000 | 10,000 | 15,000 | 71,000 | 12,000 | -16,000 | 29,000 | 2,000 | 6,000 | |||||||||||||||||||||||||||||||||||||||||||||||
deferred payments related to purchase of interest in business | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
fair market value of initial contingent consideration related to purchase of interest of businesses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of medicare accelerated and advance funds | -14,054,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of clinics and fixed assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of non controlling interest-permanent equity | -223,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | -6,320,000 | -10,658,000 | 24,343,000 | -4,338,000 | -3,130,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings in unconsolidated affiliate | -326,000 | -274,000 | -192,000 | -304,000 | -340,000 | -339,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in other assets | 965,000 | -735,000 | -438,000 | 60,000 | -476,000 | 221,000 | -1,243,000 | -565,000 | 866,000 | 112,000 | -1,238,000 | 757,000 | -2,282,000 | -119,000 | 106,000 | -690,000 | -3,343,000 | 805,000 | 735,000 | 655,000 | -2,719,000 | 1,772,000 | 2,095,000 | 2,095,000 | -1,056,000 | 170,000 | 263,000 | 38,000 | 55,000 | 355,000 | 111,000 | 496,000 | -1,142,000 | 741,000 | 208,000 | ||||||||||||||||||||||||||||||||||||||||||
increase (decrease ) in accounts payable and accrued expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sales of redeemable non-controlling interest-temporary | 57,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from revolving line of credit | 17,000,000 | 7,000,000 | 40,000,000 | 0 | 26,000,000 | 35,000,000 | 123,000,000 | 65,000,000 | 68,000,000 | 60,000,000 | 80,000,000 | 35,000,000 | 11,000,000 | 88,000,000 | 35,000,000 | 30,000,000 | 61,000,000 | 19,000,000 | 24,000,000 | 24,000,000 | 36,000,000 | 19,000,000 | 30,000,000 | 14,000,000 | 17,000,000 | 32,000,000 | 40,000,000 | 35,000,000 | 44,000,000 | 49,000,000 | 24,000,000 | 17,000,000 | 34,000,000 | 22,000,000 | 35,300,000 | 48,000,000 | 29,000,000 | 62,350,000 | 25,900,000 | 31,950,000 | 30,600,000 | 30,600,000 | 24,000,000 | 23,500,000 | 24,000,000 | 8,400,000 | 24,900,000 | 51,700,000 | 38,300,000 | 4,000,000 | 9,500,000 | 9,000,000 | 8,300,000 | 19,500,000 | 7,000,000 | 6,500,000 | 5,250,000 | 5,700,000 | 8,600,000 | 0 | 9,500,000 | 2,800,000 | 0 | ||||||||||||||
payments on revolving line of credit | -9,000,000 | 0 | -144,000,000 | -31,000,000 | -42,000,000 | -70,000,000 | -46,000,000 | -60,000,000 | -71,000,000 | -61,000,000 | -92,000,000 | -20,000,000 | -40,000,000 | -41,000,000 | -28,000,000 | -28,000,000 | -40,000,000 | -26,000,000 | -22,000,000 | -31,000,000 | -32,000,000 | -27,000,000 | -6,000,000 | -20,000,000 | -30,000,000 | -41,500,000 | -54,000,000 | -40,500,000 | -19,000,000 | -17,500,000 | -27,000,000 | -34,000,000 | -33,800,000 | -48,500,000 | -23,500,000 | -36,500,000 | -27,500,000 | -36,600,000 | -27,600,000 | -27,600,000 | -22,700,000 | -27,400,000 | -28,200,000 | -7,700,000 | -27,800,000 | -41,100,000 | -27,300,000 | -4,700,000 | -4,000,000 | -12,600,000 | -15,600,000 | -9,000,000 | -10,000,000 | -13,700,000 | -7,250,000 | -4,500,000 | |||||||||||||||||||||
payment on term loan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes receivable related to sale of partnership interest - redeemable non-controlling interest | 2,155,000 | 532,000 | 0 | 104,000 | 287,000 | 0 | 90,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | 221,000 | -1,768,000 | 1,770,000 | 2,175,000 | 2,132,000 | 4,396,000 | -1,868,000 | 979,000 | 2,181,000 | 576,000 | 903,000 | -368,000 | -1,369,000 | 971,000 | -1,741,000 | 3,303,000 | 2,118,000 | 7,912,000 | -1,363,000 | -574,000 | -1,162,000 | -108,000 | 64,000 | 343,000 | -142,000 | 21,000 | 81,000 | 471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
increase in other assets | 1,897,000 | -7,609,000 | 2,846,000 | -1,865,000 | -894,000 | 1,555,000 | -2,536,000 | -144,000 | 546,000 | -1,039,000 | -148,000 | 4,000 | -396,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(decrease ) increase in accounts payable and accrued expenses | -1,846,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of non controlling interest-permanent | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income including non-controlling interest and earnings from unconsolidated affiliates | 3,348,000 | 12,821,000 | 15,256,000 | 11,982,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of partnership interest | 96,000 | 0 | 309,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
derecognition (write-off) of goodwill - closed clinics | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of goodwill | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of non-controlling interest, permanent equity | 0 | -124,000 | -57,000 | -99,000 | -181,000 | -54,000 | -40,000 | -290,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sales of partnership interest, clinics and fixed assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sale of non-controlling interest - permanent | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(payment) receipt of medicare accelerated and advance funds | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes receivable related to sale of partnership interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unrealized gain on cash flow hedge | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sales of partnership interest, clinics and fixed assets | 0 | 736,000 | 4,000 | 139,000 | 304,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on revaluation of put-right liability | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of businesses - contingent consideration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes payable due to purchase of non-controlling interest, permanent equity | 0 | 296,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on revaluation of put-right liability | -603,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sales of non-controlling interest-permanent | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in patient accounts receivable | -1,904,000 | -2,188,000 | -637,000 | -4,688,000 | -3,218,000 | -4,763,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | 157,000 | 454,000 | 443,000 | 298,000 | 0 | 258,000 | 595,000 | 349,000 | 478,000 | 510,000 | 559,000 | 343,000 | 652,000 | 599,000 | 580,000 | 526,000 | 497,000 | 1,512,000 | -495,000 | 599,000 | 14,000 | 258,000 | 264,000 | 248,000 | 156,000 | 225,000 | 235,000 | 246,000 | 200,000 | 312,000 | 345,000 | 0 | 115,000 | 118,000 | 119,000 | 119,000 | 101,000 | 116,000 | 139,000 | 283,000 | 10,000 | 127,000 | 95,000 | 93,000 | 40,000 | 24,000 | 56,000 | 173,000 | 90,000 | 5,000 | 82,000 | 198,000 | 104,000 | 100,000 | 197,000 | 16,000 | 21,000 | 29,000 | 11,000 | ||||||||||||||||||
purchase of business - payable to common shareholders of acquired business | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
note receivables related to sale of partnership interest | 627,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short swing profit settlement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of redeemable non-controlling interest - notes payable | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivables related to sale of partnership interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income including non-controlling interests | 17,472,000 | 11,886,000 | 18,627,000 | 15,763,000 | 14,763,000 | 3,338,000 | 12,015,000 | 13,069,000 | 19,800,000 | 12,375,000 | 13,673,000 | 11,879,000 | 13,236,000 | 10,054,000 | 8,706,000 | 6,594,000 | 6,390,000 | 6,034,000 | 556,000 | 7,972,000 | 10,060,000 | 7,680,000 | 8,064,000 | 9,117,000 | 6,151,000 | 7,263,000 | 7,418,000 | 9,420,000 | 6,323,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income including non-controlling interests to net cash fromoperating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions to non-controlling interests, permanent and temporary equity | -4,133,000 | -5,265,000 | -4,108,000 | -8,516,000 | -3,366,000 | -2,341,000 | -5,373,000 | -2,928,000 | -5,358,000 | -2,576,000 | -5,176,000 | -3,735,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of businesses - payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income including non-controlling interests to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of redeemable non-controlling interest - temporary equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sales of partnership interest and clinics | 152,000 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payable related to purchase of redeemable non-controlling interest, temporary equity | 4,829,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of goodwill - closed clinics | 0 | 0 | 0 | 1,859,000 | 69,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments to settle mandatorily redeemable non-controlling interests | 0 | 0 | 0 | -265,000 | -131,000 | 0 | 0 | -2,230,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
medicare accelerated and advance payment funds | 1,130,000 | 63,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
notes receivables related to sale of partnership interest | 324,000 | 284,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provision for doubtful accounts | 1,279,000 | 739,000 | 1,361,000 | 1,450,000 | 962,000 | 1,240,000 | 1,206,000 | 1,501,000 | 890,000 | 1,151,000 | 1,061,000 | 956,000 | 930,000 | 888,000 | 898,000 | 1,078,000 | 917,000 | 956,000 | 1,089,000 | 1,067,000 | 1,061,000 | 991,000 | 1,018,000 | 1,090,000 | 1,054,000 | 950,000 | 1,007,000 | 1,095,000 | 1,089,000 | 1,192,000 | 1,259,000 | 1,280,000 | 1,117,000 | 1,231,000 | 1,426,000 | 504,000 | 624,000 | 778,000 | 695,000 | 734,000 | 1,034,000 | 772,000 | 1,001,000 | 869,000 | 706,000 | 843,000 | 747,000 | 735,000 | 748,000 | 813,000 | 691,000 | 501,000 | 631,000 | 566,000 | |||||||||||||||||||||||
payable due to purchase of redeemable non-controlling interest | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of partnership interest, net of tax | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in other liabilities | 106,000 | 239,000 | -577,000 | -1,956,000 | 2,660,000 | 173,000 | -845,000 | 170,000 | 209,000 | 1,000 | 76,000 | -356,000 | 261,000 | 82,000 | 365,000 | 220,000 | 184,000 | 195,000 | 645,000 | -37,000 | 56,000 | 56,000 | -1,340,000 | -12,000 | 43,000 | -12,000 | -882,000 | 192,000 | 207,000 | 208,000 | 575,000 | 168,000 | 106,000 | -45,000 | 961,000 | -20,000 | -584,000 | 58,000 | 234,000 | 51,000 | 117,000 | 68,000 | 126,000 | -23,000 | 242,000 | -7,000 | 187,000 | ||||||||||||||||||||||||||||||
payable related to purchase of partnership interest - settlement of redeemable non-controlling interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of non-controlling interest - payable | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on derecognition of debt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in mandatorily redeemable non-controlling interests | 4,510,000 | 668,000 | 3,490,000 | 2,911,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of majority interest in businesses | -232,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sales of non-controlling interest-permanent equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of partnership interest | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in other liabilities | -438,000 | -263,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business | -2,831,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business - seller financing portion | 3,772,000 | 228,000 | 0 | 400,000 | 400,000 | 150,000 | 500,000 | 0 | 750,000 | 900,000 | 486,000 | 14,000 | 0 | 500,000 | 0 | 850,000 | 500,000 | 0 | 0 | 400,000 | 400,000 | 400,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable related to sale of partnership interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of redeemable non-controlling interest | -2,053,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of non-controlling interest | -139,000 | -27,000 | 1,000 | -246,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of businesses, net of cash acquired | -64,000 | -7,185,000 | -8,357,000 | -761,000 | -2,942,000 | -75,000 | -17,995,000 | -15,670,000 | -10,665,000 | 0 | -59,000 | -12,899,000 | 33,000 | -8,022,000 | -6,445,000 | -30,000 | -1,490,000 | -10,625,000 | -125,000 | -36,500,000 | -130,000 | -5,783,000 | -4,215,000 | -4,215,000 | -527,000 | -222,000 | -6,090,000 | -1,090,000 | -1,302,000 | -9,351,000 | 32,000 | -93,000 | -8,785,000 | -8,042,000 | -103,000 | ||||||||||||||||||||||||||||||||||||||||||
sale of non-controlling interest | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of non-controlling interest - seller financing portion | -113,000 | -14,000 | 0 | 514,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment to settle redeemable non-controlling interest - financing portion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
receivable from sale of non-controlling interests | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale and disposal of fixed assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (cash from) provided by financing activities | 2,466,000 | -15,240,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions to non-controlling interests | -2,208,000 | -1,874,000 | -1,033,000 | -1,728,000 | -937,000 | 2,553,000 | -3,067,000 | -3,591,000 | -1,613,000 | -1,930,000 | -3,317,000 | -1,589,000 | -2,846,000 | -2,085,000 | -3,569,000 | -1,413,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from equity-based rewards | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income tax | -5,155,000 | 1,276,000 | -735,000 | -250,000 | -2,709,000 | 1,518,000 | 1,461,000 | 2,709,000 | 1,051,000 | 1,565,000 | 565,000 | 2,387,000 | 1,466,000 | 842,000 | 1,580,000 | 2,912,000 | 253,000 | -577,000 | -219,000 | -219,000 | 1,203,000 | 1,489,000 | -564,000 | 1,610,000 | 2,401,000 | 482,000 | 585,000 | 365,000 | -652,000 | 651,000 | 737,000 | -284,000 | 524,000 | 128,000 | 8,000 | 54,000 | |||||||||||||||||||||||||||||||||||||||||
sale of non-controlling interest, net of purchases | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends paid to shareholders - funded | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from equity-based rewards | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of non-controlling interests | 1,130,000 | -414,000 | 138,000 | -1,524,000 | -1,834,000 | -609,000 | -359,000 | -492,000 | -53,000 | -2,112,000 | -2,833,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sale of non-controlling interests | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from equity-based awards | 242,000 | 233,000 | 323,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends to shareholders - funded | -2,128,000 | -2,128,000 | -2,129,000 | -2,125,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from equity-based awards | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revaluation of redeemable non-controlling interests | 0 | 0 | 0 | 202,000 | 1,639,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from exercise of equity-based awards | -323,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale or abandonment of assets | 16,000 | 46,000 | 25,000 | 58,000 | 19,000 | 72,000 | 4,000 | 27,000 | 83,000 | 51,000 | 68,000 | 45,000 | 81,000 | 14,000 | 16,000 | 6,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from shared-based compensation | -386,000 | -159,000 | -271,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(decrease) in accounts payable and accrued expenses | -5,976,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in other long term liabilities | -547,000 | 262,000 | 665,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends to shareholders | -1,863,000 | -1,474,000 | -1,467,000 | -1,210,000 | -1,210,000 | -1,211,000 | -1,207,000 | -1,207,000 | -5,834,000 | -1,066,000 | -1,059,000 | -1,058,000 | -946,000 | -953,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of notes payable | -8,000 | -408,000 | -200,000 | -250,000 | 0 | -325,000 | -250,000 | 0 | -225,000 | -184,000 | -50,000 | -50,000 | -150,000 | -100,000 | -150,000 | 0 | 0 | -100,000 | -279,000 | -258,000 | -353,000 | -405,000 | -548,000 | -73,000 | -124,000 | -434,000 | -215,000 | -114,000 | -167,000 | -115,000 | -140,000 | -166,000 | -68,000 | ||||||||||||||||||||||||||||||||||||||||||||
tax benefit from share-based compensation | 386,000 | 159,000 | 271,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash - end of period | 7,586,000 | -1,585,000 | 14,557,000 | 2,890,000 | -3,827,000 | 16,761,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of business and sale or abandonment of assets | 17,000 | -14,000 | 15,000 | 19,000 | 65,000 | 19,000 | 56,000 | 58,000 | 150,000 | -558,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of goodwill - closed clinic | 34,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of business and fixed assets | 8,000 | 4,000 | 5,000 | 22,000 | 16,000 | 14,000 | 14,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale of business and fixed assets | 14,000 | 14,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from exercise of stock options | -422,000 | -311,000 | -89,000 | -126,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from stock options exercised | 33,000 | 33,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from stock options exercised | 311,000 | 89,000 | 126,000 | 244,000 | 197,000 | 126,000 | 58,000 | 180,000 | 227,000 | 395,000 | 288,000 | 36,000 | 4,000 | 8,000 | 0 | 0 | 50,000 | 3,000 | 75,000 | 7,000 | 68,000 | 100,000 | 9,000 | 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of stock options | 0 | 1,000 | 1,000 | 16,000 | 316,000 | 81,000 | 7,000 | 0 | 0 | 402,000 | 28,000 | 65,000 | 126,000 | 69,000 | 145,000 | 228,000 | 11,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash | 2,890,000 | -3,827,000 | 3,863,000 | 457,000 | 483,000 | -1,674,000 | 1,487,000 | 2,544,000 | -4,295,000 | 5,042,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash - beginning of period | 0 | 0 | 12,898,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income including noncontrolling interests | 7,374,000 | 5,609,000 | 5,609,000 | 5,794,000 | 6,298,000 | 7,314,000 | 6,812,000 | 10,142,000 | 5,853,000 | 7,603,000 | 6,185,000 | 6,358,000 | 6,177,000 | 7,034,000 | 5,131,000 | 4,207,000 | 5,140,000 | 6,034,000 | 4,593,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income including noncontrolling interests to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on purchase price settlement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of noncontrolling interests | -956,000 | -956,000 | -930,000 | -349,000 | -400,000 | -565,000 | -1,504,000 | -3,050,000 | -15,870,000 | -15,000 | -129,000 | -338,000 | -198,000 | -17,000 | -2,194,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sale of noncontrolling interests | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
settlement of purchase price | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions to noncontrolling interests | -2,816,000 | -1,594,000 | -1,594,000 | -2,482,000 | -2,099,000 | -2,832,000 | -1,919,000 | -2,485,000 | -2,685,000 | -2,608,000 | -1,989,000 | -2,344,000 | -2,405,000 | -2,594,000 | -2,237,000 | -2,009,000 | -2,329,000 | -2,707,000 | -2,393,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase and retire of common stock | 0 | 0 | -2,939,000 | -2,647,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of noncontrolling interest - seller financing portion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable—other | -426,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of non-controlling interests, net of sales | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds on sale of non controlling interest, fixed assets and business | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash—beginning of period | 9,983,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash—end of period | 10,440,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business—seller financing portion | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of noncontrolling interests, net of sales | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net proceeds on sale of fixed assets and business | 30,000 | 22,000 | 6,000 | 1,000 | 1,000 | 3,000 | 2,000 | 770,000 | 125,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
benefit from doubtful accounts | 1,089,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease (increase) in accounts receivable - other | 74,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents—beginning of period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents—end of period | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of noncontrolling interest—seller financing portion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable — other | 287,000 | -165,000 | -703,000 | -409,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase and retirement of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash — beginning of period | 0 | 0 | 9,179,000 | 0 | 0 | 6,429,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash — end of period | 483,000 | -1,674,000 | 10,666,000 | 2,544,000 | -4,295,000 | 11,471,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business — seller financing portion | 0 | 250,000 | 50,000 | 0 | 225,000 | 556,000 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of noncontrolling interest — seller financing portion | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents — beginning of period | 0 | 0 | 0 | 10,113,000 | 0 | 0 | 7,976,000 | 0 | 0 | 10,952,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents — end of period | -2,897,000 | -1,113,000 | -642,000 | 11,081,000 | 1,080,000 | -1,124,000 | 9,197,000 | -2,402,000 | -1,125,000 | 13,093,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividend to shareholders | -943,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
recognition of deferred rent subsidies | -130,000 | -124,000 | -121,000 | -117,000 | -108,000 | -105,000 | -122,000 | -96,000 | -105,000 | -109,000 | -112,000 | -130,000 | -103,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in accounts receivable — other | -128,000 | 65,000 | -172,000 | -62,000 | -660,000 | 1,000 | -6,000 | 197,000 | 100,000 | 130,000 | 173,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(increase) in other assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable securities — available for sale | 0 | 0 | -440,000 | -1,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds on sale of marketable securities — available for sale | 0 | 1,900,000 | 0 | 640,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business — issuance of common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of goodwill | -39,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the period for : | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | 2,233,000 | 2,531,000 | 2,855,000 | 2,385,000 | 2,486,000 | 2,120,000 | 2,303,000 | 1,829,000 | 1,484,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interests in earnings of subsidiary limited partnerships | 1,853,000 | 1,583,000 | 1,977,000 | 1,672,000 | 1,576,000 | 1,369,000 | 1,467,000 | 1,315,000 | 1,201,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of minority interests, included in goodwill | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions to minority investors in subsidiary limited partnerships | -2,058,000 | -1,848,000 | -1,916,000 | -1,473,000 | -1,387,000 | -1,605,000 | -1,196,000 | -1,463,000 | -881,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repurchase of common stock | -860,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents — beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents — end of year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from exercise of stock options | -50,000 | -3,000 | -75,000 | -68,000 | -100,000 | -9,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in patient account receivable | 880,000 | -682,000 | -2,755,000 | -1,175,000 | -956,000 | -1,001,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in accounts receivable – other | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of minority interest, included in goodwill | -739,000 | -372,000 | -285,000 | -383,000 | 0 | -129,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment on revolving line of credit | -6,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilites: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of business, net of cash acquired | -576,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
closure costs — write-off of goodwill | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment charge — goodwill | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash transactions during the period: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
conversion of series c notes into common stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on sale or abandonment of fixed assets | 12,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable -- other | -137,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(increase) decrease in other assets | -107,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of minority interests, included in goodwill | -800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents -- beginning of period | 15,002,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
note payable purchase of minority interest purchase of business — seller financing portion |